Systems and methods for regulating protein function by a protease

Engineered proteins with protease recognition sequences and fusion domains address solubility and aggregation issues, enabling controlled activation and detection of protein function and secretion, enhancing biological research capabilities.

WO2026236638A1PCT designated stage Publication Date: 2026-11-12PIONEER BIOLABS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027320
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for regulating protein function and detecting protein secretion face challenges due to issues such as solubility and aggregation of split fluorescent protein-based biosensors, as well as difficulties in targeted degradation, limiting the ability to study proteins in a temporally controlled manner.

Method used

Engineering a protein with a protease recognition sequence that destabilizes intramolecular interactions, allowing proteolytic cleavage to stabilize the protein and enhance its activity, using proteases like TEV to cleave specific sites, and incorporating fusion proteins with membrane association domains and biosensors for detection.

Benefits of technology

The engineered proteins enable controlled activation and detection of protein function and secretion, improving solubility and stability, and allowing for precise regulation and monitoring of biological processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027320_12112026_PF_FP_ABST
    Figure US2026027320_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are fusion proteins, methods for regulating activity of a protein, and systems thereof. The fusion protein comprises a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein. The first portion of the parent protein is C-terminal or N-terminal to the second portion of the parent protein in the protein. The sequence of amino acid residues is terminal to both the first portion of the parent protein and the second portion of the parent protein. Systems for regulating activity of a protein, methods for regulating protein activity, polynucleotides, polypeptides, vectors, and cells are also described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 890564-0003-W001

[0002] SYSTEMS AND METHODS FOR REGULATING PROTEIN FUNCTION BY A PROTEASE

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims priority to U. S. Provisional Patent Application No. 63 / 803,318 filed on May 9, 2025, which is incorporated by reference herein in its entirety.

[0005] REFERENCE TO SEQUENCE LISTING

[0006] This application was filed with a Sequence Listing XML in ST.26 XML format in accordance with 37 C. F. R. § 1.831 and PCT Rule 13ter. The Sequence Listing XML file submitted in the USPTO Patent Center, “890564-0003-W001_sequence_listing_XML_8-MAY-2026.xml,” was created on May 8, 2026, contains 18 sequences, has a file size of 50.6 kilobytes (51,912 bytes), and is incorporated by reference in its entirety into the specification.

[0007] BACKGROUND

[0008] Proteins perform a wide variety of functions in living cells, and the ability to regulate protein activity in a controlled manner has broad applications across many fields of biological research. Some proteins are naturally synthesized with amino acid sequences that inhibit their function until those sequences are cleaved by a protease. However, many useful proteins become active immediately after synthesis and folding, limiting the ability to study or utilize them in a temporally controlled manner.

[0009] Fluorescent proteins, such as green fluorescent protein (GFP), have become valuable tools in biological research. Genetically encoded biosensors incorporating fluorescent proteins can detect chemical signals such as calcium ions, pH, or small molecules by converting them into measurable fluorescent signals. These biosensors have been useful for understanding biological processes, including the visualization of signaling events in cells.

[0010] In addition to detecting chemical signals, biosensors can also be used to detect biological activity such as protease activity. Many protease biosensors are based on splitting a fluorescent protein into two non-fluorescent fragments that can reassemble and catalyze the formation of a chromophore capable of producing a fluorescent signal. By adding protein domains to at least one of the fragments, reassembly can be inhibited until one of the fragments is cleaved by a protease. However, split fluorescent protein-based protease biosensors can present challenges because the two halves may not be completely folded, leading to problems with solubility and aggregation. Additionally, targeted degradation of the two halves can be more difficult compared to biosensors comprising a single protein.890564-0003-W001

[0011] Detecting the subcellular localization and secretion of proteins is another area of interest in cell biology. Monitoring when and where proteins are transported within cells or secreted from cells can provide insights into cellular processes and protein trafficking pathways. However, existing approaches for detecting protein secretion may face limitations related to sensor complexity, signal detection, or compatibility with various cellular systems.

[0012] What are needed are improved compositions, methods, and systems for regulating protein function and for detecting protein secretion in cells.

[0013] SUMMARY

[0014] One embodiment described herein is an engineered protein, comprising a first portion of a parent protein a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein; and a protease recognition sequence wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein. In one aspect, the second portion of the parent protein is operably linked to the N-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence is operably linked to the N-terminus of the second portion of the parent protein. In another aspect, the protease recognition sequence is directly fused to the N-terminus of the second portion of the parent protein. In another aspect, the protease recognition sequence is operably linked to the C-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence is directly fused to the C-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence destabilizes at least one intramolecular interaction of the engineered protein, such that proteolytic cleavage of the protease recognition sequence at least partially stabilizes the destabilized intramolecular interaction. In another aspect, the intramolecular interaction is a hydrophobic interaction between at least two amino acid residues that form part of a hydrophobic cluster in the parent protein. In another aspect, the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1152. In another aspect, the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1161. In another aspect, the protease recognition sequence reduces activity of the engineered protein relative to the parent protein. In another aspect, proteolytic cleavage of the protease recognition sequence increases biological activity of the engineered protein. In another aspect, proteolytic cleavage of the protease recognition890564-0003-W001

[0015] sequence restores the engineered protein to an active conformation. In another aspect, the parent protein is selected from an enzyme, a fluorescent protein, a transcription factor, or a receptor. In another aspect, the parent protein is a fluorescent protein. In another aspect, the fluorescent protein is a superfolder variant of green fluorescent protein. In another aspect, the superfolder variant of green fluorescent protein comprises one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. In another aspect, the protease recognition sequence is cleavable by a protease selected from TEV protease, Thrombin, caspase, Factor Xa, SUMO Protease, Trypsin, Enterokinase, or Endoproteinase AspN. In another aspect, the protease recognition sequence is configured to be recognized by Tobacco Etch Virus protease. In another aspect, the protease recognition sequence comprises ENLYFQ / X (SEQ ID NO: 17), where X represents an amino acid residue following a cleavage site. In another aspect, at least a portion of a beta sheet near a C-terminus of the first portion of the parent protein is sequentially last to fold. In another aspect, the protein comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In another aspect, the protein comprises an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 16. In another aspect, the protein is expressed by a nucleotide sequence having at least 90-99% identity to SEQ ID NO: 7, 9, 11, 13, or 15. In another aspect, the protein is expressed by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

[0016] Another embodiment described herein is a method for regulating activity of a protein, comprising providing a protein comprising a first portion of a parent protein a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein a protease recognition sequence wherein the sequence of amino acid residues disrupts an interaction between at least two amino acid residues of the protein; and contacting the protein with the protease to cleave the protease recognition sequence, thereby restoring the interaction between the at least two amino acid residues. In one aspect, the first portion of the parent protein is C-terminal to the second portion of the parent protein in the protein. In another aspect, the first portion of the parent protein is N-terminal to the second portion of the parent protein in the protein. In another aspect, the parent protein is a fluorescent protein, and wherein restoring the interaction increases fluorescence of the protein. In another aspect, the fluorescent protein is a superfolder variant of green fluorescent890564-0003-W001

[0017] protein comprising one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. In another aspect, the protease is Tobacco Etch Virus protease.

[0018] Another embodiment described herein is a fusion protein, comprising a translocated protein domain a membrane association domain a post-translational modification site; and a biosensor. In one aspect, translocated protein domain comprises a signal peptide. In another aspect, signal peptide is positioned at an N-terminus of the fusion protein. In another aspect, membrane association domain comprises a transmembrane domain. In another aspect, transmembrane domain is a single-pass transmembrane domain. In another aspect, post-translational modification site comprises a protease cleavage site. In another aspect, protease cleavage site comprises a Tobacco Etch Virus protease cleavage site. In another aspect, post-translational modification site comprises a phosphorylation site, a glycosylation site, or a SUMOylation site. In another aspect, biosensor comprises a split fluorescent protein, a Förster resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing protein. In another aspect, biosensor comprises a fluorescent protein. In another aspect, translocated protein domain comprises a carbohydrase, an alpha-amylase, a protease, a subtilisin, insulin, beta-lactoglobulin, ovalbumin, albumin, an antibody, ora single-chain antibody fragment. In another aspect, fusion protein comprises an amino acid sequence having at least 95-99% identity to SEQ ID NO: 8 or comprises an amino acid sequence of SEQ ID NO: 8. In another aspect, fusion protein is expressed by a nucleotide sequence having at least 95-99% identity to SEQ ID NO: 7 or a nucleotide sequence comprising SEQ ID NO: 7.

[0019] Another embodiment described herein is a system for regulating activity of a protein comprising a fusion protein comprising a translocated protein domain a membrane association domain a post-translational modification site; and a biosensor; and a membrane-localized protein comprising an enzymatic domain configured to modulate the post-translational modification site of the fusion protein. In one aspect, the membrane-localized protein is localized to a plasma membrane through S-palmitoylation or myristoylation. In another aspect, the enzymatic domain comprises a Tobacco Etch Virus protease. In another aspect, the enzymatic domain comprises a kinase, a SUMO-protein, or a glycosylation enzyme. In another aspect, modulation of the post-translational modification site comprises cleavage of the fusion protein, phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein. In another aspect, the biosensor comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 10.

[0020] Another embodiment described herein is a method for regulating activity of a protein, comprising expressing in a cell a fusion protein comprising a translocated protein domain, a890564-0003-W001

[0021] membrane association domain, a post-translational modification site, and an biosensor expressing in the cell a membrane-localized protein comprising an enzymatic domain allowing the enzymatic domain to modulate the post-translational modification site of the fusion protein; and detecting a change in a characteristic conferred by the biosensor. In one aspect, the post-translational modification site comprises a protease cleavage site, and wherein modulating the post-translational modification site comprises cleaving the fusion protein at the protease cleavage site. In another aspect, the biosensor comprises a fluorescent protein, and wherein detecting the change comprises detecting a change in fluorescence. In another aspect, the cell is an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, or a human embryonic kidney cell.

[0022] Another embodiment described herein is a nucleic acid molecule encoding the biosensors described herein or the fusion proteins described herein.

[0023] Another embodiment described herein is a vector comprising the nucleic acid molecules described herein.

[0024] Another embodiment described herein is a cell comprising the system described herein, the nucleic acid molecules described herein, or the vectors described herein.

[0025] Another embodiment described herein is a use of the proteins described herein; the methods described herein, the fusion proteins described herein; or the systems described herein for regulating protein function.

[0026] DESCRIPTION OF THE DRAWINGS FIG. 1A-C shows diagrams illustrating exemplary proteins including an engineered superfolder green fluorescent protein and circularly permutated variants thereof. FIG. 1A shows an exemplary engineered superfolder green fluorescent protein (sfGFP) showing beta sheets (or strands) 7 and 8 represented by large hollow arrows (SEQ ID NO: 2). The small black squares represent amino acid residues 1152 and 1161. The N- and C-termini are also shown. FIG. 1B shows an exemplary circularly permutated sfGFP where strand 7 is at the N terminus and strand 8 is at the C-terminus (SEQ ID NO: 12). FIG. 1C shows an exemplary circularly permutated sfGFP where the N-terminus and the C-terminus are in the middle of strand 8 and a sequence of amino acids recognized by a protease are located close to one of the termini, in this case the N-terminus (SEQ ID NO: 14). In this example, additional amino acids recognized by the Tobacco Etch Virus (TEV) protease at the N-terminus (ENLYFQ / N) (SEQ ID NO: 18) disrupts at least one contact between amino acid residues of the protein. Disrupting the contact between amino acid890564-0003-W001

[0027] residues results in the diminution or abrogation of the fluorescence emitted by the green fluorescent protein.

[0028] FIG 2 shows the soluble fraction from eight different cultures of E. coli run on an SDS-PAGE gel stained with coomassie dye. The plus sign indicates that the culture was grown in LB with approximately 0.4% arabinose w / v. The minus sign indicates the culture was grown in LB without arabinose. The arrows indicate bands where the biosensor ran to or where one of the two cleavage fragments of the biosensor ran to after the biosensor was cleaved by TEV protease. Wild type cells comprise no plasmids. TEV cells comprise the plasmid corresponding to SEQ ID NO: 3. Biosensor cells comprise the plasmid corresponding to SEQ ID NO: 9. TEV plus Biosensor cells comprise the plasmids corresponding to SEQ ID NO: 9 and SEQ ID NO: 3.

[0029] FIG 3 shows the mean fluorescence intensity units of eight different cultures of E. coli measured on a microplate reader. A dark gray bar indicates that the culture was grown in LB with approximately 0.4% Arabinose w / v. A light gray bar indicates the culture was grown in LB without Arabinose. The area of each well was scanned and the data from 21 points was collected and averaged. Wild type cells comprise no plasmids. TEV cells comprise the plasmid corresponding to SEQ ID NO: 3. Biosensor cells comprise the plasmid corresponding to SEQ ID NO: 9. TEV plus Biosensor cells comprise the plasmids corresponding to SEQ ID NO: 9 and SEQ ID NO: 3.

[0030] FIG. 4 shows a flowchart of a method for regulating activity of a protein.

[0031] FIG. 5 shows a flowchart of a method for detecting activity of a protein.

[0032] FIG. 5 shows a system diagram of a system for modulating activity of a protein.

[0033] DETAILED DESCRIPTION

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of biochemistry, molecular biology, and chemistry described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control the interpretation of terms. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.

[0035] As used herein, terms such as “include,” “including,” “contain,” “containing,” “having,” and the like mean “comprising.” The present disclosure also contemplates other embodiments “comprising,” “consisting essentially of,” and “consisting of” the embodiments or elements presented herein, whether explicitly set forth or not. As used herein, “comprising,” is an “open-890564-0003-W001

[0036] ended” term that does not exclude additional, unrecited elements or method steps. As used herein, “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim.

[0037] As used herein, the term “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, “a,” “an,” or “the” means “one or more” unless otherwise specified.

[0038] As used herein, the term “or” can be conjunctive or disjunctive.

[0039] As used herein, the term “and / or” refers to both the conjunctive and disjunctive.

[0040] As used herein, the term “substantially” means to a great or significant extent, but not completely.

[0041] As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value, or within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system. In one aspect, the term “about” refers to any values, including both integers and fractional components that are within a variation of up to ± 10% of the value modified by the term “about.” Alternatively, “about” can mean within 3 or more standard deviations, per the practice in the art. Alternatively, such as with respect to biological systems or processes, the term “about” can mean within an order of magnitude, in some embodiments within 5-fold, and in some embodiments within 2-fold, of a value. As used herein, the symbol means “about” or “approximately.” All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1-2.0 includes 0.1, 0.2, 0.3, 0.4... 2.0. If the end points are modified by the term “about,” the range specified is expanded by a variation of up to ± 10% of any value within the range or within 3 or more standard deviations, including the end points, or as described above in the definition of “about.”

[0042] As used herein, the terms “room temperature,” “RT,” or “ambient temperature” refer to the typical temperature in an indoor laboratory setting. In one aspect, the laboratory setting is climate controlled to maintain the temperature at a substantially uniform temperature or with a specific range of temperatures. In one aspect, “room temperature” refers a temperature of about 15-30 °C, including all integers and endpoints within the specified range. In another aspect, “room temperature” refers a temperature of about 15-30 °C; about 20-30 °C; about 22-30 °C; about 25-30 °C; about 27-30 °C; about 15-22 °C; about 15-25 °C; about 15-27 °C; about 20-22 °C;890564-0003-W001

[0043] about 20-25 °C; about 20-27 °C; about 22-25 °C; about 22-27 °C; about 25-27 °C; about 15 °C ± 10%; about 20 °C ± 10%; about 22 °C ± 10%; about 25 °C ± 10%; about 27 °C ± 10%; ~20 °C, ~22 °C, ~25 °C, or ~27 °C, at standard atmospheric pressure.

[0044] As used herein, the terms “control,” or “reference” are used herein interchangeably. A “reference” or “control” level may be a predetermined value or range, which is employed as a baseline or benchmark against which to assess a measured result. “Control” also refers to control experiments or control cells.

[0045] As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “vector,” “polypeptide,” and “protein” have their common meanings as would be understood by a biochemist of ordinary skill in the art. Standard single letter nucleotides (A, C, G, T, U) and standard single letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein.

[0046] “Coding sequence” or “encoding nucleic acid” as used herein means the nucleic acids (RNA or DNA molecule) that comprise a nucleotide sequence which encodes a protein. The coding sequence can further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in cells to which the nucleic acid is administered. The coding sequence may be codon optimized.

[0047] “Complement” or “complementary” as used herein means a nucleic acid can mean Watson-Crick (e.g., A-T / U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules. “Complementarity” refers to a property shared between two nucleic acid sequences, such that when they are aligned antiparallel to each other, the nucleotide bases at each position will be complementary.

[0048] “Fusion protein” as used herein refers to a chimeric protein created through the joining of two or more genes that originally coded for separate proteins. The translation of the fusion gene results in a single polypeptide with functional properties derived from each of the original proteins.

[0049] “Genetic construct” as used herein refers to the DNA or RNA molecules that comprise a polynucleotide that encodes a protein. The coding sequence includes initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in cells. As used herein, the term “expressible form” refers to gene constructs that contain the necessary regulatory elements operable linked to a coding sequence that encodes a protein such that when present in a cell, the coding sequence will be expressed.890564-0003-W001

[0050] The term “heterologous” as used herein refers to nucleic acid comprising two or more subsequences that are not found in the same relationship to each other in nature. For instance, a nucleic acid that is recombinantly produced typically has two or more sequences from unrelated genes synthetically arranged to make a new functional nucleic acid, for example, a promoter from one source and a coding region from another source. The two nucleic acids are thus heterologous to each other in this context. When added to a cell, the recombinant nucleic acids would also be heterologous to the endogenous genes of the cell. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (for example, a “fusion protein,” where the two subsequences are encoded by a single nucleic acid sequence).

[0051] “Identical” or “identity” as used herein in the context of two or more polynucleotide or polypeptide sequences means that the sequences have a specified percentage of residues that are the same over a specified region. The percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent. Identity may be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0 or CLUSTAL Omega.

[0052] “Nucleic acid” or “oligonucleotide” or “polynucleotide” as used herein means at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a polynucleotide also encompasses the complementary strand of a depicted single strand. Many variants of a polynucleotide may be used for the same purpose as a given polynucleotide. Thus, a polynucleotide also encompasses substantially identical polynucleotides and complements thereof. A single strand provides a probe that may hybridize to a target sequence under stringent hybridization conditions. Thus, a polynucleotide also encompasses a probe that hybridizes under stringent hybridization conditions. Polynucleotides may be single stranded or double stranded or may contain portions of both double stranded and single stranded sequence. The polynucleotide can be nucleic acid, natural or synthetic, DNA, genomic DNA, cDNA, RNA, or a hybrid, where the polynucleotide can contain890564-0003-W001

[0053] combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including, for example, uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine. Polynucleotides can be obtained by chemical synthesis methods or by recombinant methods.

[0054] “Operably linked” as used herein means that expression of a gene is under the control of a promoter with which it is spatially connected. A promoter may be positioned 5' (upstream) or 3' (downstream) of a gene under its control. The distance between the promoter and a gene may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function. Nucleic acid or amino acid sequences are “operably linked” (or “operatively linked”) when placed into a functional relationship with one another. For instance, a promoter or enhancer is operably linked to a coding sequence if it regulates, or contributes to the modulation of, the transcription of the coding sequence. Operably linked DNA sequences are typically contiguous, and operably linked amino acid sequences are typically contiguous and in the same reading frame. However, since enhancers generally function when separated from the promoter by up to several kilobases or more and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous. Similarly, certain amino acid sequences that are non-contiguous in a primary polypeptide sequence may nonetheless be operably linked due to, for example folding of a polypeptide chain. With respect to fusion polypeptides or protein and non-protein linkages such as a fusion protein linked to a membrane, the terms “operatively linked” and “operably linked” can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked. For example, a first portion of a parent protein may be operably linked to the second portion of a parent protein so that the first and second portions retain their functional characteristics.

[0055] A “peptide” or “polypeptide” is a linked sequence of two or more amino acids linked by peptide bonds. The polypeptide can be natural, synthetic, or a modification or combination of natural and synthetic. Peptides and polypeptides include proteins such as binding proteins, receptors, and antibodies. The terms “polypeptide,” “protein,” and “peptide” are used interchangeably herein. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as “domains,” for example, enzymatic domains, extracellular domains, transmembrane domains, pore domains, and cytoplasmic tail domains. “Domains” are portions of a polypeptide that form a compact unit of the polypeptide890564-0003-W001

[0056] and are typically 15 to 350 amino acids long. Exemplary domains include domains with translocation activity, indicator activity, or membrane association activity. Typical domains are made up of sections of lesser organization such as stretches of beta-sheet and alpha-helices. “Tertiary structure” refers to the complete three-dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three-dimensional structure formed by the noncovalent association of independent tertiary units. A “motif is a portion of a polypeptide sequence and includes at least two amino acids. A motif may be 2 to 20, 2 to 15, or 2 to 10 amino acids in length. In some embodiments, a motif includes 3, 4, 5, 6, or 7 sequential amino acids. A domain may be comprised of a series of the same type of motif.

[0057] “Promoter” as used herein means a synthetic or naturally derived molecule which is capable of conferring, activating, or enhancing expression of a nucleic acid in a cell. A promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and / or to alter the spatial expression and / or temporal expression of same. A promoter may also comprise distal enhancer or repressor elements, which may be located as much as several thousand base pairs from the start site of transcription. A promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals. A promoter may regulate the expression of a gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter, human U6 (hU6) promoter, CMV IE promoter, pTDH3 promoter, pCCW12 promoter, pPGK1 promoter, pHHF2 promoter, pTEF1 promoter, pTEF2 promoter, pHHF1 promoter, pHTB2 promoter, pRPL18B promoter, pALD6 promoter, pPAB1 promoter, pRET2 promoter, pRNR1 promoter, pSAC6 promoter, pRNR2 promoter, pPOP6 promoter, pRAD27 promoter, pPSP2 promoter, pREV1 promoter, pMFA1 promoter, pMFa2 promoter, pGAL1 promoter, and pCUP1 promoter.

[0058] The term “recombinant” when used with reference to, for example, a cell, nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (naturally occurring) form of the cell or express890564-0003-W001

[0059] a second copy of a native gene that is otherwise normally or abnormally expressed, under expressed, or not expressed at all.

[0060] “Substantially identical” can mean that a first and second polypeptide or polynucleotide sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 amino acids or nucleotides, respectively.

[0061] “Variant” used herein with respect to a polynucleotide means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto.

[0062] “Variant” with respect to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or polypeptide or to promote an immune response. Variant can mean a functional fragment thereof. Variant can also mean multiple copies of a polypeptide. The multiple copies can be in tandem or separated by a linker. A conservative substitution of an amino acid, for example, replacing an amino acid with a different amino acid of similar properties (for example, hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes may be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. Mol. Biol. 157, 105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes may be substituted and still retain protein function. For example, amino acids having hydropathic indexes of ±2 are substituted. The hydrophilicity of amino acids may also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide. Substitutions may be performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are890564-0003-W001

[0063] understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.

[0064] “Vector” as used herein means a nucleic acid sequence containing an origin of replication. A vector may be a viral vector, bacteriophage, bacterial artificial chromosome, or yeast artificial chromosome. A vector may be a DNA or RNA vector. A vector may be a self-replicating extrachromosomal vector, and preferably, is a DNA plasmid. For example, the vector may encode a fusion protein described herein.

[0065] As used herein, the term “parent protein” refers to a protein from which a modified or engineered protein is derived. A parent protein may serve as a template or starting point for creating circularly permutated variants or other engineered proteins. In some cases, a parent protein may be a fluorescent protein such as green fluorescent protein or a superfolder variant thereof.

[0066] As used herein, the term “circularly permutated” or “circular permutation” refers to a rearrangement of a protein sequence in which the original N-terminus and C-terminus are joined, and new termini are created at different positions within the protein sequence. In a circularly permutated protein, the linear order of amino acid residues differs from the parent protein, but the overall three-dimensional structure may be preserved. For example, a circularly permutated superfolder green fluorescent protein may have beta sheet 7 at the N-terminus and beta sheet 8 at the C-terminus.

[0067] As used herein, the term “first portion” refers to a segment of a parent protein that, in the engineered or circularly permutated protein, is positioned C-terminal to a second portion of the parent protein. The first portion may comprise one or more secondary structure elements such as beta sheets or alpha helices.

[0068] As used herein, the term “second portion” refers to a segment of a parent protein that is C-terminal to the first portion in the parent protein but is positioned N-terminal to the first portion in the engineered or circularly permutated protein.

[0069] As used herein, the phrase “N-terminal to” refers to a second polypeptide sequence that is positioned at the N-terminus of a first polypeptide and connected by a linkage, often a peptide bond. There may be linker amino acids or small peptide sequence between the second polypeptide and the first polypeptide.

[0070] As used herein, the phrase “C-terminal to” refers to a second polypeptide sequence that is positioned at the C-terminus of a first polypeptide and connected by a linkage, often a peptide890564-0003-W001

[0071] bond. There may be linker amino acids or small peptide sequence between the second polypeptide and the first polypeptide.

[0072] As used herein, the phrase “directly fused” refers to a second polypeptide that is linked to a first polypeptide, often by a peptide bond.

[0073] As used herein, the term “protease” refers to an enzyme that catalyzes the hydrolysis of peptide bonds in proteins. A protease may recognize and cleave a specific sequence of amino acid residues. Examples of proteases include, but are not limited to, Tobacco Etch Virus (TEV) protease, Thrombin, Factor Xa, SUMO Protease, Trypsin, Enterokinase, Furin, Endopeptidase, intramembrane proteases, and gamma secretase. In addition, Endopeptidase cleaves at the N-terminal side of their specific recognition residues such as Asp-N, which would make it possible to place the recognition at the C-terminus instead of the N-terminus.

[0074] As used herein, the term “fluorescent protein” refers to a protein capable of emitting light upon excitation. Fluorescent proteins may include green fluorescent protein (GFP), superfolder green fluorescent protein (sfGFP), mTurquoise2, and variants thereof. Fluorescent proteins may be used as indicator domains or as components of biosensors.

[0075] As used herein, the term “superfolder variant” refers to a variant of a fluorescent protein, such as green fluorescent protein, that exhibits enhanced folding properties, increased solubility, or improved stability compared to the wild-type protein. A superfolder variant of green fluorescent protein may comprise one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V.

[0076] As used herein, the term “hydrophobic cluster” refers to a group of hydrophobic amino acid residues that interact with one another within a protein structure. Hydrophobic clusters may contribute to protein folding and stability. In some cases, disruption of a hydrophobic cluster may affect the activity or fluorescence of a protein.

[0077] As used herein, the term “beta sheet” refers to a secondary structure element in a protein formed by hydrogen bonding between segments of the polypeptide backbone. Beta sheets may comprise multiple beta strands arranged in parallel or antiparallel orientations. In green fluorescent protein and variants thereof, beta sheets form a barrel structure that surrounds the chromophore.

[0078] As used herein, the term “fusion protein” refers to a chimeric protein created through the joining of two or more genes or protein-coding sequences that originally coded for separate proteins. Translation of a fusion gene results in a single polypeptide with functional properties derived from each of the original proteins.890564-0003-W001

[0079] As used herein, the term “translocated protein domain” refers to a domain of a fusion protein that is configured to be transported or exported from one cellular compartment to another or from a cell. A translocated protein domain may comprise a signal peptide that mediates translocation across a membrane. Examples of translocated protein domains include carbohydrases, alpha-amylases, proteases, subtilisins, insulin, beta-lactoglobulin, ovalbumin, albumin, antibodies, and single-chain antibody fragments.

[0080] As used herein, the term “membrane association domain” refers to a domain of a protein that is capable of associating with or linking to a cellular membrane. The membrane may be a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane. A membrane association domain may comprise a transmembrane domain or a linker for linking the protein to a membrane.

[0081] As used herein, the term “post-translational modification site” refers to a site within a protein that is capable of being modified after translation. Post-translational modifications may include proteolytic cleavage, phosphorylation, glycosylation, or SUMOylation. A post-translational modification site may be modified when a translocated protein domain is localized to a distinct subcellular compartment or plasma membrane.

[0082] As used herein, the term “indicator domain” refers to a domain of a protein that confers a detectable characteristic to a cell or system. An indicator domain may comprise a fluorescent protein, a split fluorescent protein, a Förster resonance energy transfer (FRET) fluorescent protein, a transcription factor, or an antibiotic metabolizing protein. The indicator domain may remain a constituent of a cell after export of a translocated protein domain.

[0083] As used herein, the term “membrane-localized protein” refers to a protein that is associated with or attached to a cellular membrane. A membrane-localized protein may be localized to a plasma membrane through S-palmitoylation, myristoylation, or other lipid modifications. A membrane-localized protein may comprise an enzymatic domain.

[0084] As used herein, the term “enzymatic domain” refers to a domain of a protein that possesses catalytic activity. An enzymatic domain may be configured to modulate a post-translational modification site of another protein. Examples of enzymatic domains include proteases such as Tobacco Etch Virus protease, kinases, SUMO-proteins, and glycosylation enzymes.

[0085] As used herein, the term “signal peptide” refers to a short amino acid sequence, typically located at the N-terminus of a protein, that directs the protein to a specific cellular location or mediates translocation of the protein across a membrane. A signal peptide may be cleaved from the protein during or after translocation.890564-0003-W001

[0086] As used herein, the term “transmembrane domain” refers to a segment of a protein that spans a cellular membrane. A transmembrane domain may be a single-pass transmembrane domain or a multi-pass transmembrane domain. Transmembrane domains typically comprise hydrophobic amino acid residues that interact with the lipid bilayer of the membrane.

[0087] As used herein, the term “protease cleavage site” refers to a specific sequence of amino acid residues within a protein that is recognized and cleaved by a protease. A protease cleavage site may comprise a Tobacco Etch Virus protease cleavage site having the sequence ENLYFQ / X, (SEQ ID NO: 17) where x represents the amino acid residue following the cleavage site. Cleavage at a protease cleavage site may separate domains of a fusion protein or restore activity to an engineered protein, In some aspects, Tobacco Etch Virus protease cleavage site having the sequence ENLYFQ / N, (SEQ ID NO: 18).

[0088] As used herein, the term “chromophore” refers to a chemical group within a protein that is responsible for absorbing light and producing color or fluorescence. In fluorescent proteins such as green fluorescent protein, the chromophore is formed through a post-translational cyclization reaction involving amino acid residues within the protein. The chromophore may be surrounded by a beta barrel structure that protects the chromophore and modulates the fluorescent properties of the protein.

[0089] As used herein, the term “biosensor” refers to an analytical device or molecule that combines a biological component with a physicochemical detector to detect or measure a target analyte or biological activity. A biosensor may comprise a fluorescent protein or a circularly permutated variant thereof. In some cases, a biosensor may be configured to detect protease activity by producing a change in fluorescence upon cleavage of a protease recognition sequence.

[0090] As used herein, the term “expression vector” refers to a nucleic acid molecule capable of directing the expression of a gene or coding sequence in a host cell. An expression vector may comprise regulatory elements such as a promoter, a ribosome binding site, and a terminator sequence. In some cases, an expression vector may be a plasmid, a viral vector, or an artificial chromosome.

[0091] As used herein, the term “host cell” refers to a cell into which a nucleic acid, such as a polynucleotide or expression vector, has been introduced. A host cell may be a prokaryotic cell or a eukaryotic cell. In some cases, a host cell may be an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, or a human embryonic kidney cell.890564-0003-W001

[0092] As used herein, the term “promoter” refers to a nucleic acid sequence that directs transcription of a gene or coding sequence. A promoter may be constitutive or inducible. In some cases, a promoter may be an arabinose-inducible promoter or a tetracycline-inducible promoter.

[0093] As used herein, the term “linker” refers to a sequence of amino acid residues that connects two domains or portions of a protein. A linker may provide flexibility between domains or may serve to position domains in a particular spatial arrangement. In some cases, a linker may comprise glycine and serine residues.

[0094] As used herein, the term “S-palmitoylation” refers to a post-translational modification in which a palmitate group is attached to a cysteine residue of a protein through a thioester linkage. S-palmitoylation may anchor a protein to a cellular membrane.

[0095] As used herein, the term “myristoylation” refers to a post-translational modification in which a myristate group is attached to an N-terminal glycine residue of a protein. Myristoylation may anchor a protein to a cellular membrane.

[0096] As used herein, the term “SUMOylation” refers to a post-translational modification in which a small ubiquitin-like modifier (SUMO) protein is covalently attached to a target protein. SUMOylation may modulate protein function, localization, or stability.

[0097] As used herein, the term “phosphorylation” refers to a post-translational modification in which a phosphate group is added to an amino acid residue of a protein, typically a serine, threonine, or tyrosine residue. Phosphorylation may be catalyzed by a kinase and may modulate protein activity or interactions.

[0098] As used herein, the term “glycosylation” refers to a post-translational modification in which a carbohydrate moiety is attached to a protein. Glycosylation may occur at asparagine residues (N-linked glycosylation) or at serine or threonine residues (O-linked glycosylation).

[0099] As used herein, the term “Förster resonance energy transfer” or “FRET” refers to a mechanism of energy transfer between two light-sensitive molecules. FRET may occur when a donor fluorophore in an excited state transfers energy to an acceptor fluorophore through nonradiative dipole-dipole coupling. The efficiency of FRET may depend on the distance between the donor and acceptor fluorophores.

[0100] As used herein, the term “split fluorescent protein” refers to a fluorescent protein that has been divided into two or more non-fluorescent fragments. The fragments may reassemble to form a functional fluorescent protein capable of producing a fluorescent signal. Split fluorescent proteins may be used in complementation assays to detect protein-protein interactions or protease activity.890564-0003-W001

[0101] As used herein, the term “single-pass transmembrane domain” refers to a transmembrane domain that spans a cellular membrane once. A single-pass transmembrane domain may comprise a hydrophobic alpha helix of approximately 20 to 25 amino acid residues.

[0102] As used herein, the term “secretory pathway” refers to the cellular pathway through which proteins are transported from the endoplasmic reticulum through the Golgi apparatus to the plasma membrane or extracellular space. Proteins entering the secretory pathway may comprise a signal peptide that directs the protein to the endoplasmic reticulum.

[0103] I nt. Pat. App. Pub. No. WO 2024 / 097893 A2 describes systems and methods for detection of protein secretion, which is incorporated by reference herein in its entirety for all teachings and disclosure thereof.

[0104] Engineered Proteins with Protease-Regulated Activity

[0105] The present disclosure relates to proteins, systems, and methods for regulating protein function through proteolytic cleavage. In some aspects, engineered proteins may be configured such that the activity of the engineered proteins is modulated by a protease. Such engineered proteins may include circularly permutated variants of parent proteins, where the linear arrangement of amino acid residues differs from the parent protein while the overall three-dimensional structure may be preserved.

[0106] In some cases, an engineered protein may comprise a sequence of amino acid residues configured to be recognized by a protease. The sequence of amino acid residues may disrupt an interaction between amino acid residues within the engineered protein, thereby affecting the activity of the engineered protein. Upon cleavage of the sequence of amino acid residues by the protease, the interaction between the amino acid residues may be restored, and the activity of the engineered protein may be modulated. In some aspects, the parent protein may be a fluorescent protein, and cleavage of the sequence of amino acid residues may increase fluorescence of the engineered protein.

[0107] The present disclosure also relates to fusion protein-based systems for detecting protein secretion. In some aspects, a fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. A membrane-localized protein comprising an enzymatic domain may modulate the post-translational modification site of the fusion protein. Modulation of the post-translational modification site may result in a detectable change in a characteristic conferred by the indicator domain, thereby enabling detection of protein secretion or subcellular localization events.890564-0003-W001

[0108] In some cases, the post-translational modification site may comprise a protease cleavage site, and modulation may comprise cleavage of the fusion protein at the protease cleavage site. Cleavage of the fusion protein may separate the translocated protein domain from the indicator domain. The indicator domain may comprise a fluorescent protein, and detection of protein secretion may comprise detecting a change in fluorescence.

[0109] In some aspects, a protein may comprise a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The second portion of the parent protein may be C-terminal to the first portion of the parent protein in the parent protein. In the protein, the first portion of the parent protein may be C-terminal to the second portion of the parent protein. In some cases, the first portion of the parent protein may be N-terminal to the second portion of the parent protein in the protein. The sequence of amino acid residues may be terminal to both the first portion of the parent protein and the second portion of the parent protein.

[0110] Circularly Permutated Fluorescent Proteins

[0111] Circular permutation refers to a rearrangement of a protein sequence in which the original N-terminus and C-terminus are joined, and new termini are created at different positions within the protein sequence. In a circularly permutated protein, the linear order of amino acid residues differs from the parent protein, but the overall three-dimensional structure may be preserved. The first portion of the parent protein may comprise one or more secondary structure elements such as beta sheets or alpha helices. The second portion of the parent protein may be a segment of the parent protein that is C-terminal to the first portion in the parent protein but is positioned N-terminal to the first portion in the engineered or circularly permutated protein.

[0112] In some cases, the parent protein may be a fluorescent protein such as green fluorescent protein or a superfolder variant thereof. A superfolder variant of green fluorescent protein may exhibit enhanced folding properties, increased solubility, or improved stability compared to the wild-type protein. The superfolder variant of green fluorescent protein may comprise one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V.

[0113] FIG. 1A-1C depict diagrams illustrating exemplary proteins including an engineered superfolder green fluorescent protein and circularly permutated variants thereof. As shown in FIG. 1A-1C, an engineered superfolder green fluorescent protein (sfGFP) includes a beta sheet 7 and a beta sheet 8 (SEQ ID NO: 2). The beta sheet 7 and the beta sheet 8 are represented by large hollow arrows within a cylindrical structure representing the barrel-like fold of the fluorescent protein. The beta sheet 7 and the beta sheet 8 are positioned adjacent to each other within the890564-0003-W001

[0114] barrel structure. Amino acid residues 1152 and 1161 are represented within the engineered sfGFP structure as black boxes in the [3-strands.

[0115] In some aspects, a circularly permutated sfGFP may have the beta sheet 7 at the N-terminus and the beta sheet 8 at the C-terminus. In some cases, the N-terminus and the C-terminus of a circularly permutated sfGFP may be positioned in the middle of the beta sheet 8. The beta sheet 7 and the beta sheet 8 form part of a barrel structure that surrounds the chromophore in green fluorescent protein and variants thereof.

[0116] In some aspects, at least a portion of a beta sheet near a C-terminus of the first portion of the parent protein may be sequentially last to fold. The sequential folding of the beta sheet near the C-terminus of the first portion may facilitate insertion of the protease recognition sequence and may affect the activity of the engineered protein prior to protease cleavage.

[0117] Protease Recognition Sequences and Disruption of Amino Acid Interactions

[0118] In some aspects, a protein may comprise a sequence of amino acid residues configured to be recognized by a protease. The sequence of amino acid residues may be configured to disrupt an interaction between at least two amino acid residues of the protein. The disruption of the interaction between the at least two amino acid residues may affect the activity of the protein. In some cases, the parent protein may be a fluorescent protein. When the parent protein is a fluorescent protein, disruption of the interaction between the at least two amino acid residues may result in decreased fluorescence of the protein.

[0119] In some aspects, the sequence of amino acid residues recognized by the protease may be positioned at or near a terminus of the circularly permutated protein to disrupt at least one contact between amino acid residues of the protein. The sequence of amino acid residues may prevent proper contact between amino acid residues that contribute to the three-dimensional structure of the engineered protein.

[0120] In some cases, the at least two amino acid residues may comprise a hydrophobic cluster in the parent protein. The hydrophobic cluster may comprise amino acid residues that contribute to folding of the protein. For example, in a circularly permutated superfolder green fluorescent protein, amino acid residues 1152 and 1161 may be part of a hydrophobic cluster of amino acid residues that contribute to folding of the protein. Disruption of the hydrophobic cluster may affect the activity or fluorescence of the protein.

[0121] In some aspects, an interaction between 1152 and an amino acid residue interacting with 1152 may be disrupted by the sequence of amino acid residues. In some cases, an interaction between 1161 and an amino acid residue interacting with 1161 may be disrupted by the sequence890564-0003-W001

[0122] of amino acid residues. The sequence of amino acid residues recognized by the protease may disrupt an interaction between 1152 and an amino acid residue interacting with 1152, or an interaction between 1161 and an amino acid residue interacting with 1161.

[0123] Protease Recognition and Activity Modulation

[0124] In some aspects, a protein may comprise a sequence of amino acid residues configured to be recognized by a protease. The sequence of amino acid residues may be configured to disrupt an interaction between at least two amino acid residues of the protein. The disruption of the interaction between the at least two amino acid residues may affect the activity of the protein. In some cases, the parent protein may be a fluorescent protein. When the parent protein is a fluorescent protein, disruption of the interaction between the at least two amino acid residues may result in decreased fluorescence of the protein.

[0125] In some aspects, cleavage of the sequence of amino acid residues by the protease may increase fluorescence of the protein. Upon cleavage of the sequence of amino acid residues by the protease, the interaction between the at least two amino acid residues may be restored, and the fluorescence of the protein may increase. The increase in fluorescence may be detected and used as an indicator of protease activity.

[0126] In some cases, the fluorescent protein may be a superfolder variant of green fluorescent protein. The superfolder variant of green fluorescent protein may comprise at least one mutation selected from the group consisting of S30R, Y39N, N105T, Y145F, 1171V, and A206V (SEQ ID NO: 2). The superfolder variant may exhibit enhanced folding properties or increased solubility compared to wild-type green fluorescent protein.

[0127] In some aspects, at least one of the amino acid residues disrupted by the sequence of amino acid residues may comprise a hydrophobic cluster in the parent protein. The hydrophobic cluster may comprise amino acid residues that contribute to folding of the protein. In some cases, an interaction between 1152 and an amino acid residue interacting with 1152 may be disrupted by the sequence of amino acid residues. In some cases, an interaction between 1161 and an amino acid residue interacting with 1161 may be disrupted by the sequence of amino acid residues. The amino acid residues 1152 and 1161 may be part of a hydrophobic cluster of amino acid residues that contribute to folding of the protein.

[0128] In some aspects, the sequence of amino acid residues may be configured to be recognized by Tobacco Etch Virus protease. The Tobacco Etch Virus protease may recognize and cleave a sequence having the motif ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site. In some cases, the sequence of amino acid890564-0003-W001

[0129] residues recognized by the Tobacco Etch Virus protease may be positioned at or near a terminus of the circularly permutated protein. Cleavage of the sequence of amino acid residues by the Tobacco Etch Virus protease may restore the interaction between the at least two amino acid residues and increase fluorescence of the protein.

[0130] Fusion Proteins

[0131] Provided herein are fusion proteins. The fusion proteins may include a translocated protein domain, a membrane association domain, a post-translational modification (PTM) site, and an indicator domain. A fusion protein may be encoded by a nucleotide sequence. A fusion protein may comprise an amino acid sequence.

[0132] The fusion proteins may also comprise a transmembrane domain such as a single-pass transmembrane domain. The fusion proteins may further comprise a cleavage site. Cleavage of the fusion protein at the cleavage site may separate the translocated protein domain from the remainder of the fusion protein.

[0133] At least a portion of the translocated protein domain may be configured to be exported from a cell. The translocated protein domain may comprise a heterologous protein or an endogenous protein. The translocated protein domain may comprise a carbohydrase, an alphaamylase, a protease, or a subtilisin. Other translocated protein domains may include insulin, betalactoglobulin, ovalbumin, albumin, antibodies, single-chain antibody fragments (scFv), membrane proteins, DNA polymerases, RNA polymerases, helicases, restriction enzymes, nucleases, single stranded DNA binding proteins, or fluorescent proteins. The carbohydrase, the alpha-amylase, the protease, and the subtilisin may be heterologous or endogenous.

[0134] A fusion protein may comprise a signal peptide. In particular, the translocated protein domain of the fusion protein may comprise a signal peptide. The signal peptide may mediate translocation of at least a portion of the translocated protein domain across a membrane. The fusion protein may comprise the signal peptide at the N-terminus of the fusion protein.

[0135] The membrane association domain may be capable of operably linking to a membrane. The membrane may be a membrane of the endoplasmic reticulum, a membrane of the golgi apparatus, a vacuole membrane, or a plasma membrane. A fusion protein may comprise a linker. In particular, the membrane association domain may comprise a linker for linking the fusion protein to a membrane.

[0136] The PTM site may be capable of being modified when the translocated protein domain is localized to a distinct subcellular compartment or plasma membrane. The PTM site may be modified when the translocated protein domain is localized to a distinct subcellular compartment890564-0003-W001

[0137] or plasma membrane. The subcellular compartment may be the endoplasmic reticulum, the golgi apparatus, or a vacuole of a cell. The PTM site may include a tobacco etch virus protease cleavage site, an intramembrane protease cleavage site, a cleavage site for gamma secretase, a phosphorylation site, or a glycosylation site.

[0138] The indicator domain may confer a detectable characteristic to a cell that comprises the fusion protein upon modification of the PTM site. The indicator domain may remain a constituent of the cell after export of the translocated protein domain. The indicator domain may include a cytoplasmic protein, a transcription factor, an antibiotic metabolizing protein, a fluorescent protein, a split fluorescent protein, or a Förster resonance energy transfer fluorescent protein.

[0139] In some aspects, a protein may comprise an amino acid sequence having at least 95% identity to SEQ ID NO: 10, 12, or 14. In some cases, a protein may comprise an amino acid sequence having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise the amino acid sequence of SEQ ID NO: 10, 12, or 14.

[0140] SEQ ID NO: 10 corresponds to aTEV-N164-A163 biosensor polypeptide. TheTEV-N164-A163 biosensor polypeptide of SEQ ID NO: 10 may comprise a circularly permutated superfolder green fluorescent protein with a Tobacco Etch Virus protease cleavage site positioned to disrupt interactions between amino acid residues of the protein. The Tobacco Etch Virus protease cleavage site may comprise the sequence ENLYFQ / N (SEQ ID NO: 18), where cleavage occurs after the glutamine residue. In some cases, the Tobacco Etch Virus protease cleavage site may be inserted before N164 and end on A163, which may reduce the fluorescence of the protein prior to cleavage.

[0141] SEQ ID NO: 12 corresponds to a circularly permutated sfGFP polypeptide. The circularly permutated sfGFP polypeptide of SEQ ID NO: 12 may comprise a circularly permutated superfolder green fluorescent protein where beta sheet 7 is at the N-terminus and beta sheet 8 is at the C-terminus.

[0142] SEQ ID NO: 14 corresponds to a protease biosensor polypeptide. The protease biosensor polypeptide of SEQ ID NO: 14 may comprise a circularly permutated superfolder green fluorescent protein where beta sheet 7 is at the N-terminus and beta sheet 8 is at the C-terminus. In some cases, the N-terminus and the C-terminus of the protease biosensor polypeptide may be positioned in the middle of beta sheet 8. The protease biosensor polypeptide may comprise a sequence of amino acid residues recognized by a protease located close to one of the termini of the circularly permutated protein. The sequence of amino acid residues may disrupt at least one contact between amino acid residues of the protein, resulting in decreased fluorescence. Upon890564-0003-W001

[0143] cleavage of the sequence of amino acid residues by the protease, the interaction between the amino acid residues may be restored, and the fluorescence of the protein may increase.

[0144] In some aspects, a protein may be encoded by a nucleotide sequence having at least 95% identity to SEQ ID NO: 7, 9, 11, 13, or 15. In some cases, a protein may be encoded by a nucleotide sequence having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 7, 9, 11, 13, or 15. In some aspects, a protein may be encoded by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

[0145] SEQ ID NO: 7 corresponds to a plasmid expressing a fusion protein comprising an Ost1 signal peptide, an alpha mating factor pro-domain, mTurquoise2, a WSC4 transmembrane domain, and a TEV-N164-A163 biosensor. SEQ ID NO: 9 corresponds to a plasmid expressing a TEV-N164-A163 biosensor. In some cases, the plasmid corresponding to SEQ ID NO: 9 may comprise an arabinose-inducible promoter and may be used to express the biosensor encoded by SEQ ID NO: 9. SEQ ID NO: 11 corresponds to a circularly permutated sfGFP nucleotide sequence. SEQ ID NO: 13 corresponds to a protease biosensor DNA sequence.

[0146] A polynucleotide having a nucleotide sequence at least 95% to 99% identical to a reference nucleotide sequence encoding a polypeptide may have a nucleotide sequence that is identical to the reference sequence except that the polynucleotide sequence may include up to about 5 to 1 point mutations, additions, or deletions per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In some cases, up to 5% of the nucleotides in the reference sequence may be deleted, added, or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. Mutations of the reference sequence may occur at the 5'- or 3'-terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The same may be applicable to polypeptide sequences at least 95% to 99% identical to a reference polypeptide sequence.

[0147] Translocated Protein Domains

[0148] In some aspects, a translocated protein domain may comprise a carbohydrase, an alphaamylase, a protease, or a subtilisin. The carbohydrase, the alpha-amylase, the protease, and the subtilisin may be heterologous or endogenous to a cell in which the fusion protein is expressed.

[0149] In some cases, a translocated protein domain may comprise insulin, beta-lactoglobulin, ovalbumin, albumin, antibodies, or single-chain antibody fragments (scFv). In some aspects, a translocated protein domain may comprise membrane proteins, DNA polymerases, RNA890564-0003-W001

[0150] polymerases, helicases, restriction enzymes, nucleases, single stranded DNA binding proteins, or fluorescent proteins. The translocated protein domain may comprise a heterologous protein or an endogenous protein. At least a portion of the translocated protein domain may be configured to be exported from a cell.

[0151] Signal Peptides and Membrane Association

[0152] In some aspects, a fusion protein may comprise a signal peptide. The translocated protein domain of the fusion protein may comprise a signal peptide. The signal peptide may mediate translocation of at least a portion of the translocated protein domain across a membrane. In some cases, the fusion protein may comprise the signal peptide at the N-terminus of the fusion protein.

[0153] In some aspects, a membrane association domain may be capable of operably linking to a membrane. The membrane may be a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane. The membrane association domain may allow a fusion protein to associate with or attach to a cellular membrane during translocation through the secretory pathway.

[0154] In some cases, a fusion protein may comprise a linker. The membrane association domain may comprise a linker for linking the fusion protein to a membrane. The linker may connect the fusion protein to a membrane of a cellular compartment or to a plasma membrane.

[0155] In some aspects, a fusion protein may comprise a transmembrane domain. The transmembrane domain may be a single-pass transmembrane domain. A single-pass transmembrane domain may span a cellular membrane once and may anchor the fusion protein to the membrane. In some cases, the single-pass transmembrane domain may be derived from a membrane protein such as WSC4.

[0156] Post-Translational Modification Sites

[0157] In some aspects, a post-translational modification site may comprise a Tobacco Etch Virus protease cleavage site. The Tobacco Etch Virus protease cleavage site may have the sequence ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site. Cleavage at the Tobacco Etch Virus protease cleavage site may separate domains of a fusion protein or restore activity to an engineered protein.

[0158] In some cases, a post-translational modification site may comprise an intramembrane protease cleavage site. An intramembrane protease may cleave a fusion protein within a membrane environment. In some aspects, a post-translational modification site may comprise a890564-0003-W001

[0159] cleavage site for gamma secretase. Gamma secretase may recognize and cleave specific sequences within a fusion protein.

[0160] In some aspects, a post-translational modification site may comprise a phosphorylation site. A phosphorylation site may be modified by a kinase to add a phosphate group to an amino acid residue of a fusion protein. Phosphorylation of the fusion protein may result in a detectable change in a characteristic conferred by an indicator domain.

[0161] In some cases, a post-translational modification site may comprise a glycosylation site. A glycosylation site may be modified by a glycosylation enzyme to add a carbohydrate moiety to an amino acid residue of a fusion protein. Glycosylation of the fusion protein may result in a detectable change in a characteristic conferred by an indicator domain.

[0162] In some aspects, modification of a post-translational modification site may occur when a translocated protein domain is localized to a subcellular compartment. The subcellular compartment may be the endoplasmic reticulum of a cell. In some cases, the subcellular compartment may be the Golgi apparatus of a cell. In some aspects, the subcellular compartment may be a vacuole of a cell. Localization of the translocated protein domain to a subcellular compartment may bring the post-translational modification site into proximity with an enzymatic domain capable of modifying the post-translational modification site.

[0163] Indicator Domains

[0164] In some aspects, an indicator domain may confer a detectable characteristic to a cell that comprises a fusion protein upon modification of a post-translational modification site. The indicator domain may include a cytoplasmic protein, a transcription factor, an antibiotic metabolizing protein, a fluorescent protein, a split fluorescent protein, or a Förster resonance energy transfer (FRET) fluorescent protein.

[0165] In some cases, the indicator domain may comprise a cytoplasmic protein. A cytoplasmic protein may remain in the cytoplasm of a cell after cleavage of a fusion protein at a post-translational modification site. The cytoplasmic protein may be detected through various assays or imaging techniques.

[0166] In some aspects, the indicator domain may comprise a transcription factor. A transcription factor may regulate gene expression upon release from a fusion protein. Detection of protein secretion may be accomplished by monitoring expression of a gene regulated by the transcription factor.

[0167] In some cases, the indicator domain may comprise an antibiotic metabolizing protein. An antibiotic metabolizing protein may confer resistance to an antibiotic or may metabolize an890564-0003-W001

[0168] antibiotic to produce a detectable product Detection of protein secretion may be accomplished by monitoring cell survival in the presence of an antibiotic or by detecting a metabolic product.

[0169] In some aspects, the indicator domain may comprise a fluorescent protein. A fluorescent protein may emit light upon excitation, and detection of protein secretion may comprise detecting a change in fluorescence intensity, fluorescence localization, or fluorescence lifetime.

[0170] In some cases, the indicator domain may comprise a split fluorescent protein. A split fluorescent protein may comprise two or more fragments that reassemble to form a functional fluorescent protein. Detection of protein secretion may be accomplished by monitoring reassembly of the split fluorescent protein fragments.

[0171] In some aspects, the indicator domain may comprise a Fbrster resonance energy transfer (FRET) fluorescent protein. A FRET fluorescent protein may comprise a donor fluorophore and an acceptor fluorophore. Detection of protein secretion may be accomplished by monitoring changes in FRET efficiency between the donor fluorophore and the acceptor fluorophore.

[0172] In some cases, the indicator domain may remain a constituent of a cell after export of a translocated protein domain. The indicator domain may be retained in the cytoplasm or associated with a cellular membrane after cleavage of a fusion protein separates the translocated protein domain from the indicator domain. Retention of the indicator domain within the cell may allow for detection of protein secretion events.

[0173] Membrane-Localized Proteins and Enzymatic Domains

[0174] In some aspects, a membrane-localized protein may comprise an enzymatic domain configured to modulate a post-translational modification site of a fusion protein. The enzymatic domain may modulate the post-translational modification site through various mechanisms. In some cases, modulation may comprise cleavage of the fusion protein at a protease cleavage site. In some cases, modulation may comprise phosphorylation of the fusion protein. In some cases, modulation may comprise SUMOylation of the fusion protein. In some cases, modulation may comprise glycosylation of the fusion protein.

[0175] In some aspects, the membrane-localized protein may be localized to a plasma membrane. The membrane-localized protein may be localized to the plasma membrane through S-palmitoylation. In some cases, the membrane-localized protein may be localized to the plasma membrane through myristoylation. S-palmitoylation and myristoylation are lipid modifications that may anchor the membrane-localized protein to the plasma membrane.

[0176] In some aspects, the enzymatic domain may comprise a Tobacco Etch Virus protease. A Tobacco Etch Virus protease may recognize and cleave a sequence having the motif ENLYFQ / X890564-0003-W001

[0177] (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site. Cleavage of the fusion protein by the Tobacco Etch Virus protease may separate the translocated protein domain from the indicator domain.

[0178] In some cases, the enzymatic domain may comprise a kinase. A kinase may catalyze the transfer of a phosphate group from a donor molecule to an amino acid residue of the fusion protein. Phosphorylation of the fusion protein by the kinase may result in a detectable change in a characteristic conferred by the indicator domain.

[0179] In some aspects, the enzymatic domain may comprise a SUMO-protein. A SUMO-protein may catalyze the attachment of a small ubiquitin-like modifier (SUMO) to an amino acid residue of the fusion protein. SUMOylation of the fusion protein by the SUMO-protein may result in a detectable change in a characteristic conferred by the indicator domain.

[0180] In some cases, the enzymatic domain may comprise a glycosylation protein. A glycosylation protein may catalyze the attachment of a carbohydrate moiety to an amino acid residue of the fusion protein. Glycosylation of the fusion protein by the glycosylation protein may result in a detectable change in a characteristic conferred by the indicator domain.

[0181] Fusion Protein-Based System

[0182] Provided herein are fusion protein-based systems. “Fusion protein-based system and “system” may be used interchangeably herein. The system may be used to detect protein secretion. The system may include a fusion protein and a membrane localized protein comprising an enzymatic domain. The enzymatic domain of the membrane localized protein may modulate the PTM site of the fusion protein. Modulation may include cleavage, phosphorylation, SUMOylation, or glycosylation of the fusion protein. The membrane localized protein may be localized to the plasma membrane. The membrane localized protein may be localized to the plasma membrane through S-palmitoylation or myristoylation. The membrane localized protein may comprise a tobacco etch virus protease, a kinase, a SUMO-protein, or glycosylation proteins.

[0183] Fusion Proteins for Protein Secretion Detection

[0184] In some aspects, a fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. In some aspect, the indicator domain is a biosensor. The fusion protein may be configured to detect protein secretion events by coupling protein translocation with a detectable signal output.

[0185] In some cases, the translocated protein domain may comprise a signal peptide. The signal peptide may mediate translocation of at least a portion of the translocated protein domain across890564-0003-W001

[0186] a membrane. The signal peptide may be positioned at an N-terminus of the fusion protein. N-terminal positioning of the signal peptide follows the natural arrangement found in secreted proteins, facilitating recognition by cellular secretion machinery.

[0187] In some aspects, the translocated protein domain may comprise a carbohydrase, an alpha-amylase, a protease, or a subtilisin. The carbohydrase, the alpha-amylase, the protease, and the subtilisin may be heterologous or endogenous to a cell in which the fusion protein is expressed. In some cases, the translocated protein domain may comprise insulin, betalactoglobulin, ovalbumin, albumin, an antibody, or a single-chain antibody fragment. In some aspects, the translocated protein domain may comprise membrane proteins, DNA polymerases, RNA polymerases, helicases, restriction enzymes, nucleases, single stranded DNA binding proteins, or fluorescent proteins. At least a portion of the translocated protein domain may be configured to be exported from a cell.

[0188] In some aspects, the membrane association domain may comprise a transmembrane domain. The transmembrane domain may be a single-pass transmembrane domain. A singlepass transmembrane domain may span a cellular membrane once and may anchor the fusion protein to the membrane. In some cases, the single-pass transmembrane domain may be derived from a membrane protein such as WSC4.

[0189] In some cases, the membrane association domain may be capable of operably linking to a membrane. The membrane may be a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane. The membrane association domain may allow the fusion protein to associate with or attach to a cellular membrane during translocation through the secretory pathway.

[0190] In some aspects, the membrane association domain may comprise a linker for linking the fusion protein to a membrane. The linker may connect the fusion protein to a membrane of a cellular compartment or to a plasma membrane.

[0191] In some cases, a fusion protein may comprise an amino acid sequence having at least 95% identity to SEQ ID NO: 8. In some aspects, a fusion protein may comprise an amino acid sequence having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8. SEQ ID NO: 8 corresponds to a fusion protein comprising an Ost1 signal peptide, an alpha mating factor prodomain, mTurquoise2, a WSC4 transmembrane domain, and a TEV-N164-A163 biosensor. The Ost1 signal peptide may direct the fusion protein to the secretory pathway. The alpha mating factor pro-domain may facilitate proper processing and secretion of the fusion protein. The mTurquoise2 may serve as a fluorescent marker for tracking the fusion protein. The WSC4 transmembrane domain may anchor the fusion protein to a cellular membrane.890564-0003-W001

[0192] Protein Modulation System

[0193] In some aspects, the indicator domain may comprise biosensor comprising a split fluorescent protein. A split fluorescent protein may comprise two or more fragments that reassemble to form a functional fluorescent protein. Detection of protein secretion may be accomplished by monitoring reassembly of the split fluorescent protein fragments. The fragments of the split fluorescent protein may be non-fluorescent when separated and may produce a fluorescent signal upon reassembly.

[0194] In some cases, the indicator domain may comprise a Förster resonance energy transfer (FRET) fluorescent protein. A FRET fluorescent protein may comprise a donor fluorophore and an acceptor fluorophore. Detection of protein secretion may be accomplished by monitoring changes in FRET efficiency between the donor fluorophore and the acceptor fluorophore. Changes in FRET efficiency may result from conformational changes in the fusion protein or from separation of the donor fluorophore and the acceptor fluorophore upon modification of the post-translational modification site.

[0195] In some aspects, the indicator domain may comprise a transcription factor. A transcription factor may regulate gene expression upon release from a fusion protein. Detection of protein secretion may be accomplished by monitoring expression of a gene regulated by the transcription factor. The transcription factor may activate or repress transcription of a reporter gene upon release from the fusion protein.

[0196] In some cases, the indicator domain may comprise an antibiotic metabolizing protein. An antibiotic metabolizing protein may confer resistance to an antibiotic or may metabolize an antibiotic to produce a detectable product. Detection of protein secretion may be accomplished by monitoring cell survival in the presence of an antibiotic or by detecting a metabolic product produced by the antibiotic metabolizing protein.

[0197] In some aspects, the indicator domain may comprise a cytoplasmic protein. A cytoplasmic protein may remain in the cytoplasm of a cell after cleavage of a fusion protein at a post-translational modification site. The cytoplasmic protein may be detected through various assays or imaging techniques. In some cases, the indicator domain may be retained in the cytoplasm or associated with a cellular membrane after cleavage of a fusion protein separates the translocated protein domain from the indicator domain.

[0198] FIG. 6 illustrates a system diagram of a Protein Modulation System 300. The Protein Protein Modulation System 300 may be a system for detecting protein secretion. The Protein890564-0003-W001

[0199] Protein Modulation System 300 includes a Fusion Protein 302 and a Membrane-Localized Protein 312.

[0200] The Fusion Protein 302 comprises a Translocated Protein Domain 304, a Membrane Associated Domain 306, a Post-translational Modification Site 308, and an Indicator Domain 310. As described above, the Translocated Protein Domain 304 may comprise a signal peptide configured to mediate translocation of at least a portion of the Translocated Protein Domain 304 across a membrane. The signal peptide may be positioned at an N-terminus of the Fusion Protein 302. The Translocated Protein Domain 304 may be configured to be transported or exported from one cellular compartment to another or from a cell.

[0201] In some cases, the Membrane Associated Domain 306 may comprise a transmembrane domain. The transmembrane domain may be a single-pass transmembrane domain. The Membrane Associated Domain 306 may be capable of associating with or linking to a cellular membrane such as a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane.

[0202] In some aspects, the Post-translational Modification Site 308 may comprise a protease cleavage site. The protease cleavage site may comprise a Tobacco Etch Virus protease cleavage site. In some cases, the Post-translational Modification Site 308 may comprise a phosphorylation site, a glycosylation site, or a SUMOylation site.

[0203] In some aspects, the Indicator Domain 310 may confer a detectable characteristic to a cell that comprises the Fusion Protein 302 upon modification of the Post-translational Modification Site 308. The Indicator Domain 310 may comprise a fluorescent protein. In some cases, the Indicator Domain 310 may comprise a split fluorescent protein, a Förster resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing protein.

[0204] The Membrane-Localized Protein 312 comprises an Enzymatic Domain 314 configured to modulate the Post-translational Modification Site 308 of the Fusion Protein 302. In some aspects, the Membrane-Localized Protein 312 may be localized to a plasma membrane through S-palmitoylation or myristoylation. S-palmitoylation and myristoylation are lipid modifications that may anchor the Membrane-Localized Protein 312 to the plasma membrane. In some cases, the Membrane-Localized Protein 312 may be localized to the plasma membrane through S-palmitoylation by palmitoyltransferase Pfa4.

[0205] In some aspects, the Enzymatic Domain 314 may comprise a Tobacco Etch Virus protease. A Tobacco Etch Virus protease may recognize and cleave a sequence having the motif ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site. In some cases, the Tobacco Etch Virus protease may be fused to a C-terminal Gaplc890564-0003-W001

[0206] fragment (SEQ ID NO: 5) and integrated into a chromosome. The plasmid may express Tobacco Etch Virus protease at low levels that is palmitoylated by palmitoyltransferase Pfa4.

[0207] In some cases, the Enzymatic Domain 314 may comprise a kinase. A kinase may catalyze the transfer of a phosphate group from a donor molecule to an amino acid residue of the Fusion Protein 302. Phosphorylation of the Fusion Protein 302 by the kinase may result in a detectable change in a characteristic conferred by the Indicator Domain 310.

[0208] In some aspects, the Enzymatic Domain 314 may comprise a SUMO-protein. A SUMO-protein may catalyze the attachment of a small ubiquitin-like modifier (SUMO) to an amino acid residue of the Fusion Protein 302. SUMOylation of the Fusion Protein 302 by the SUMO-protein may result in a detectable change in a characteristic conferred by the Indicator Domain 310.

[0209] In some cases, the Enzymatic Domain 314 may comprise a glycosylation enzyme. A glycosylation enzyme may catalyze the attachment of a carbohydrate moiety to an amino acid residue of the Fusion Protein 302. Glycosylation of the Fusion Protein 302 by the glycosylation enzyme may result in a detectable change in a characteristic conferred by the Indicator Domain 310.

[0210] In some aspects, modulation of the Post-translational Modification Site 308 may comprise cleavage of the Fusion Protein 302. In some cases, cleavage of the Fusion Protein 302 may separate the Translocated Protein Domain 304 from the Indicator Domain 310. Modulation of the Post-translational Modification Site 308 may also comprise phosphorylation of the Fusion Protein 302, SUMOylation of the Fusion Protein 302, or glycosylation of the Fusion Protein 302.

[0211] In some aspects, when the Fusion Protein 302 reaches a subcellular compartment or plasma membrane where the Membrane-Localized Protein 312 is localized, the Enzymatic Domain 314 of the Membrane-Localized Protein 312 may modulate the Post-translational Modification Site 308 of the Fusion Protein 302. Modulation of the Post-translational Modification Site 308 may result in a detectable change in a characteristic conferred by the Indicator Domain 310, thereby enabling detection of protein secretion events.

[0212] Polynucleotides and Genetic Constructs

[0213] In some aspects, a polynucleotide may encode a protein as described herein. The protein may comprise a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The second portion of the parent protein may be C-terminal to the first portion of the parent protein in the parent protein. The first portion of the parent protein may be C-terminal or N-terminal to the second890564-0003-W001

[0214] portion of the parent protein in the protein. The sequence of amino acid residues may be terminal to both the first portion of the parent protein and the second portion of the parent protein.

[0215] In some cases, a polynucleotide may encode a fusion protein as described herein. The fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. The polynucleotide encoding the fusion protein may be incorporated into a genetic construct for expression in a cell.

[0216] In some aspects, genetic constructs may include polynucleotides such as vectors and plasmids. A genetic construct may be a plasmid. In some cases, a plasmid may have the nucleotide sequence of SEQ ID NO: 3. SEQ ID NO: 3 corresponds to a plasmid nucleotide sequence expressing a Tobacco Etch Virus protease. In some cases, a plasmid may have the nucleotide sequence of SEQ ID NO: 5. SEQ ID NO: 5 corresponds to a yeast integrating plasmid expressing a Tobacco Etch Virus protease with a C-terminal Gaplc fragment. In some cases, a plasmid may have the nucleotide sequence of SEQ ID NO: 7. SEQ ID NO: 7 corresponds to a plasmid expressing a fusion protein comprising an Ost1 signal peptide, an alpha mating factor pro-domain, mTurquoise2, a WSC4 transmembrane domain, and a TEV-N164-A163 biosensor. In some cases, a plasmid may have the nucleotide sequence of SEQ ID NO: 9. SEQ ID NO: 9 corresponds to a plasmid expressing a TEV-N164-A163 biosensor.

[0217] In some aspects, a genetic construct may be recombinant. A genetic construct may comprise regulatory elements for gene expression of coding sequences of a nucleic acid. The regulatory elements may include a promoter, an enhancer, an initiation codon, a stop codon, or a polyadenylation signal. In some cases, a plasmid may comprise an arabinose-inducible promoter. In some cases, a plasmid may comprise a tetracycline-inducible promoter. The genetic construct may be a plasmid. The plasmid may have the nucleotide sequence of SEQ ID NO: 3, 5, 7, or 9. The vector may be an expression vectors or system to produce protein by routine techniques and readily available starting materials including Sambrook et al., Molecular Cloning and Laboratory Manual, Second Ed., Cold Spring Harbor (1989), which is incorporated fully by reference. The construct may be recombinant. The genetic construct may comprise regulatory elements for gene expression of the coding sequences of the nucleic acid. The regulatory elements may be a promoter, an enhancer, an initiation codon, a stop codon, ora polyadenylation signal.

[0218] In some aspects, a fusion protein and a membrane-localized protein may be encoded by the same genetic construct. In some cases, a fusion protein and a membrane-localized protein may be encoded by different genetic constructs. When the fusion protein and the membrane-localized protein are encoded by different genetic constructs, the genetic constructs may be introduced into a cell separately or simultaneously.890564-0003-W001

[0219] Polynucleotide and Polypeptide Constructs

[0220] The polynucleotides described herein include variants that have substitutions, deletions, and / or additions that can involve one or more nucleotides. The variants can be altered in coding regions, non-coding regions, or both. Alterations in the coding regions can produce conservative or non-conservative amino acid substitutions, deletions, or additions. Especially preferred among these are silent substitutions, additions, and deletions, which do not alter the properties and activities of the binding.

[0221] Further embodiments described herein include nucleic acid molecules comprising polynucleotides having nucleotide sequences about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, and more preferably at least about 90-99% or 100% identical to (a) nucleotide sequences, or degenerate, homologous, or codon-optimized variants thereof, encoding polypeptides having the amino acid sequences in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16; (b) nucleotide sequences, or degenerate, homologous, or codon-optimized variants thereof, encoding polypeptides having the amino acid sequences in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16; and (c) nucleotide sequences capable of hybridizing to the complement of any of the nucleotide sequences in (a) or (b) above and capable of expressing functional polypeptides of amino acid sequences in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16.

[0222] By a polynucleotide having a nucleotide sequence at least, for example, 90-99% “identical” to a reference nucleotide sequence encoding a polypeptide is intended that the nucleotide sequence of the polynucleotide be identical to the reference sequence except that the polynucleotide sequence can include up to about 10-to-1-point mutations, additions, or deletions per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide.

[0223] In other words, to obtain a polynucleotide having a nucleotide sequence about at least 90-99% identical to a reference nucleotide sequence, up to 10% of the nucleotides in the reference sequence can be deleted, added, or substituted, with another nucleotide, or a number of nucleotides up to 10% of the total nucleotides in the reference sequence can be inserted into the reference sequence. These mutations of the reference sequence can occur at the 5'- or 3'-terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The same is applicable to polypeptide sequences about at least 90-99% identical to a reference polypeptide sequence.

[0224] As noted above, two or more polynucleotide sequences can be compared by determining their percent identity. Two or more amino acid sequences likewise can be compared by890564-0003-W001

[0225] determining their percent identity. The percent identity of two sequences, whether nucleic acid or peptide sequences, is generally described as the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100. An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2: 482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M. O. Dayhoff, ed., 5 suppl. 3: 353-358, National Biomedical Research Foundation, Washington, D. C., USA, and normalized by Gribskov, Nucl. Acids Res. 14(6): 6745-6763 (1986).

[0226] For example, due to the degeneracy of the genetic code, one having ordinary skill in the art will recognize that a large number of the nucleic acid molecules having a sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15 or degenerate, homologous, or codon-optimized variants thereof, will encode a functional polypeptide.

[0227] The polynucleotides described herein include those encoding mutations, variations, substitutions, additions, deletions, and particular examples of the polypeptides described herein. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247: 1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions.

[0228] Thus, fragments, derivatives, or analogs of the polypeptides of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16 can be (i) ones in which one or more of the amino acid residues (e.g., 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 residues, or even more) are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue). Such substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) ones in which one or more of the amino acid residues includes a substituent group (e.g., 1, 2, 3, 4, 5, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 residues or even more), or (iii) ones in which the mature polypeptide is fused with another polypeptide or compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) ones in which the additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence.890564-0003-W001

[0229] Such fragments, derivatives, and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

[0230] In addition, fragments, derivatives, or analogs of the polypeptides of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16 can be substituted with one or more conserved or non-conserved amino acid residue (preferably a conserved amino acid residue). In some cases, these polypeptides, fragments, derivatives, or analogs thereof will have a polypeptide sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16 and will comprise functional or non-functional proteins or enzymes. Similarly, additions or deletions to the polypeptides can be made either at the N- or C-termini or within non-conserved regions of the polypeptide (which are assumed to be non-critical because they have not been photogenically conserved).

[0231] As described herein, in many cases the amino acid substitutions, mutations, additions, or deletions are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein or additions or deletions to the N- or C-termini. Of course, the number of amino acid substitutions, additions, or deletions a skilled artisan would make depends on many factors, including those described herein. Generally, the number of substitutions, additions, or deletions for any given polypeptide will not be more than about 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 5, 6, 4, 3, 2, or 1.

[0232] Another embodiment described herein is a polynucleotide vector comprising one or more nucleotide sequences described herein.

[0233] Another embodiment described herein is a cell comprising one or more nucleotide sequences described herein or a polynucleotide vector described herein.

[0234] Another embodiment is a polypeptide encoded by a nucleotide sequence described herein. In one aspect, the polypeptide has at least 85% to 99% identity to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16. In another aspect, the polypeptide comprises a sequence selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16.

[0235] Another embodiment is a nucleotide sequence described herein. In one aspect, the nucleotide has at least 85% to 99% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15. In another aspect, the polypeptide comprises a sequence selected from SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, or 15.

[0236] Another embodiment described herein is a process for manufacturing one or more of the nucleotide sequence described herein or a polypeptide encoded by the nucleotide sequence described herein, the process comprising: transforming or transfecting a cell with a nucleic acid890564-0003-W001

[0237] comprising a nucleotide sequence described herein; growing the cells; optionally isolating additional quantities of a nucleotide sequence described herein; inducing expression of a polypeptide encoded by a nucleotide sequence of described herein; isolating the polypeptide encoded by a nucleotide described herein.

[0238] Another embodiment described herein is a means for manufacturing one or more of the nucleotide sequences described herein or a polypeptide encoded by a nucleotide sequence described herein, the process comprising: transforming or transfecting a cell with a nucleic acid comprising a nucleotide sequence described herein; growing the cells; optionally isolating additional quantities of a nucleotide sequence described herein; inducing expression of a polypeptide encoded by a nucleotide sequence of described herein; isolating the polypeptide encoded by a nucleotide described herein.

[0239] Another embodiment described herein is a nucleotide sequence or a polypeptide encoded by the nucleotide sequence produced by the method or the means described herein Another embodiment described herein is the use of an effective amount of a polypeptide encoded by one or more of the nucleotide sequences described herein.

[0240] Another embodiment described herein is a research tool comprising a polypeptide encoded by a nucleotide sequence described herein.

[0241] Another embodiment described herein is a reagent comprising a polypeptide encoded by a nucleotide sequence described herein.

[0242] In some aspects, the fusion protein may comprise an amino acid sequence having a specified percentage of identity to a reference sequence. The percentage of sequence identity may be calculated by optimally aligning two sequences, comparing the two sequences over a specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity.

[0243] In some cases, a protein may comprise an amino acid sequence having at least 95-99% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise an amino acid sequence having at least 95% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise an amino acid sequence having at least 96% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise an amino acid sequence having at least 97% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise an amino acid sequence having at least 98% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In some aspects, a protein may comprise an amino acid sequence having at least 99% identity to SEQ ID890564-0003-W001

[0244] NO: 8, 10, 12, 14, or 16. In some aspects, the protein is encoded by a nucleotide sequence having at least 95-99% identity to SEQ ID NO: 7, 9, 11, 13, or 15. In some aspects, the protein is encoded by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

[0245] In some cases, a protein may comprise the amino acid sequence of SEQ ID NO: 2, 6, 8, 10, 12, 14, or 16. SEQ ID NO: 10 corresponds to a TEV-N164-A163 biosensor polypeptide. SEQ ID NO: 8 corresponds to a fusion protein comprising an Ost1 signal peptide, an alpha mating factor pro-domain, mTurquoise2, a WSC4 transmembrane domain, and a TEV-N164-A163 biosensor. SEQ ID NO: 6 corresponds to a TEV protease with a C-terminal Gaplc fragment. SEQ ID NO: 14 corresponds to a protease biosensor polypeptides.

[0246] In some aspects, the TEV-N164-A163 biosensor polypeptide of SEQ ID NO: 10 may comprise a circularly permutated superfolder green fluorescent protein with a TEV protease cleavage site positioned to disrupt interactions between amino acid residues of the protein. The TEV protease cleavage site may comprise the sequence ENLYF / Q (SEQ ID NO: 18), where cleavage occurs after the glutamine residue. In some cases, the TEV protease cleavage site may be inserted before N164 and end on A163, which may reduce the fluorescence of the protein prior to cleavage.

[0247] In some aspects, the protease biosensor polypeptide of SEQ ID NO: 14 may comprise a circularly permutated superfolder green fluorescent protein where beta sheet 7 is at the N-terminus and beta sheet 8 is at the C-terminus. The protease biosensor polypeptide may comprise a sequence of amino acid residues recognized by a protease located close to one of the termini of the circularly permutated protein. The sequence of amino acid residues may disrupt at least one contact between amino acid residues of the protein, resulting in decreased fluorescence. Upon cleavage of the sequence of amino acid residues by the protease, the interaction between the amino acid residues may be restored, and the fluorescence of the protein may increase.

[0248] Compositions

[0249] In some aspects, a cell may comprise a polynucleotide encoding a protein as described herein. The protein may comprise a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. In some cases, a cell may comprise a polynucleotide encoding a fusion protein as described herein. The fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. In some aspect, the indicator domain is a biosensor.890564-0003-W001

[0250] In some aspects, a cell may comprise a system for protein modulation or detecting protein secretion. The system may comprise a fusion protein and a membrane-localized protein. The fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. The membrane-localized protein may comprise an enzymatic domain configured to modulate the post-translational modification site of the fusion protein.

[0251] In some cases, a cell may be a prokaryotic cell or a eukaryotic cell. In some aspects, a cell may be an Escherichia coli cell. In some cases, a cell may be a Saccharomyces cerevisiae cell. In some cases, a cell may be a Schizosaccharomyces pombe cell. In some cases, a cell may be a Pichia pastoris cell. In some cases, a cell may be a Yarrowia lipolytica cell. In some cases, a cell may be a Chinese hamster ovary cell. In some cases, a cell may be a murine myeloma cell. In some cases, a cell may be a human embryonic kidney cell.

[0252] Methods of Introducing Nucleic Acids

[0253] In some aspects, methods of introducing a nucleic acid into a host cell may include viral or bacteriophage infection, transfection, conjugation, protoplast fusion, polycation or lipid:nucleic acid conjugates, lipofection, electroporation, nucleofection, immunoliposomes, calcium phosphate precipitation, polyethyleneimine-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, direct micro injection, nanoparticle-mediated nucleic acid delivery, and lithium acetate and heat shock transformation. Upon delivery of genetic constructs into cells, the transfected cells may express a protein, a fusion protein, or a system for detecting protein secretion as described herein.

[0254] In some aspects, a composition may comprise DNA encoding a fusion protein-based system as described herein. The composition may comprise about 1 ng to about 100 pg of DNA encoding the fusion protein-based system. In some cases, the composition may comprise about 1 ng to about 10 ng of DNA encoding the fusion protein-based system. In some cases, the composition may comprise about 10 ng to about 100 ng of DNA encoding the fusion protein-based system. In some cases, the composition may comprise about 100 ng to about 1 pg of DNA encoding the fusion protein-based system. In some cases, the composition may comprise about 1 pg to about 10 pg of DNA encoding the fusion protein-based system. In some cases, the composition may comprise about 10 pg to about 100 pg of DNA encoding the fusion proteinbased system.

[0255] In some aspects, the composition may further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may include diluents, lubricants, binders,890564-0003-W001

[0256] disintegrants, colorants, flavors, sweeteners, antioxidants, preservatives, glidants, solvents, suspending agents, wetting agents, surfactants, emollients, propellants, humectants, powders, pH adjusting agents, and combinations thereof.

[0257] In some aspects, the composition may comprise a transfection facilitating agent. The transfection facilitating agent may include surface active agents such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles. In some cases, the transfection facilitating agent may facilitate uptake of the DNA encoding the fusion protein-based system into a host cell.

[0258] In some aspects, methods of introducing a nucleic acid into a host cell may include viral or bacteriophage infection, transfection, conjugation, protoplast fusion, polycation or lipid:nucleic acid conjugates, lipofection, electroporation, nucleofection, immunoliposomes, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, direct micro injection, nanoparticle-mediated nucleic acid delivery, and lithium acetate (LiAc) and heat shock transformation. In some cases, the method of introducing a nucleic acid into a host cell may be selected based on the type of host cell. In some aspects, lithium acetate and heat shock transformation may be used for introducing a nucleic acid into yeast cells such as Saccharomyces cerevisiae cells. In some cases, electroporation may be used for introducing a nucleic acid into bacterial cells such as Escherichia coli cells. In some aspects, lipofection may be used for introducing a nucleic acid into mammalian cells such as Chinese hamster ovary cells or human embryonic kidney cells.

[0259] The systems or genetic constructs as detailed herein, or at least one component thereof, may be formulated into a composition in accordance with standard techniques well known to those skilled in the art. The compositions can be formulated according to the mode of administration to be used. The compositions may be sterile, pyrogen free, and particulate free. An isotonic formulation may be used. Generally, additives for isotonicity may include sodium chloride, dextrose, mannitol, sorbitol, and lactose. In some cases, isotonic solutions such as phosphate buffered saline are preferred.

[0260] The composition may further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be functional molecules as vehicles, adjuvants, carriers, or diluents. The term “pharmaceutically acceptable carrier,” may be a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.890564-0003-W001

[0261] Pharmaceutically acceptable carriers include, for example, diluents, lubricants, binders, disintegrants, colorants, flavors, sweeteners, antioxidants, preservatives, glidants, solvents, suspending agents, wetting agents, surfactants, emollients, propellants, humectants, powders, pH adjusting agents, and combinations thereof. The pharmaceutically acceptable excipient may be a transfection facilitating agent, which may include surface active agents, such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. The transfection facilitating agent may be a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. The transfection facilitating agent may be poly-L-glutamate.

[0262] Delivery Methods and Cell Types

[0263] In some aspects, the composition may further comprise a transfection facilitating agent. The transfection facilitating agent may include surface active agents such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles. In some cases, the transfection facilitating agent may be a polyanion. In some cases, the transfection facilitating agent may be a polycation, including poly-L-glutamate (LGS). In some cases, the transfection facilitating agent may be a lipid.

[0264] In some aspects, systems or genetic constructs described herein, or at least one component thereof, may be administered or delivered to a cell. Methods of introducing a nucleic acid into a host cell may include viral or bacteriophage infection, transfection, conjugation, protoplast fusion, polycation or lipid:nucleic acid conjugates, lipofection, electroporation, nucleofection, immunoliposomes, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, direct micro injection, nanoparticle-mediated nucleic acid delivery, and lithium acetate (LiAc) and heat shock transformation.

[0265] In some cases, transfections may include a transfection reagent. In some aspects, several different buffers may be used for delivery of nucleic acids into cells. Upon delivery of systems or genetic constructs described herein, or at least one component thereof, or compositions comprising the same, into cells, the transfected cells may express a fusion protein or fusion protein-based system.890564-0003-W001

[0266] In some aspects, any of the delivery methods described herein may be utilized with a variety of cell types. In some cases, a cell may be an Eschericia coli cell. In some cases, a cell may be a Saccharomyces cerevisiae cell. In some cases, a cell may be a Schizosaccharomyces pombe cell. In some cases, a cell may be a Pichia pastoris cell. In some cases, a cell may be a Yarrowia lipolytica cell. In some cases, a cell may be a Chinese hamster ovary cell. In some cases, a cell may be a murine myeloma cell. In some cases, a cell may be a human embryonic kidney cell. Cells may be modified to isolate and expand clonal populations of cells that include a fusion protein or system described herein.

[0267] The systems or genetic constructs as detailed herein, or at least one component thereof, may be administered or delivered to a cell. Methods of introducing a nucleic acid into a host cell are known in the art, and any known method can be used to introduce a nucleic acid (e.g., an expression construct) into a cell. Suitable methods include, for example, viral or bacteriophage infection, transfection, conjugation, protoplast fusion, polycation or lipid mucleic acid conjugates, lipofection, electroporation, nucleofection, immunoliposomes, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery, lithium acetate (LiAc) and heat shock transformation, and the like. Several different buffers may be used, including BioRad electroporation solution, Sigma phosphate-buffered saline product #D8537 (PBS), Invitrogen OptiMEM I (OM), or Amaxa Nucleofector solution V (N. V.). Transfections may include a transfection reagent, such as Lipofectamine 2000.

[0268] Upon delivery of the presently disclosed systems or genetic constructs as detailed herein, or at least one component thereof, or the compositions comprising the same, into cells, the transfected cells may express the fusion protein or fusion protein-based system.

[0269] Cell Types

[0270] Any of the delivery methods detailed herein can be utilized with a myriad of cell types, including, but not limited to, an Eschericia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, and a human embryonic kidney cell. Cells can be modified to isolate and expand clonal populations of cells that include a fusion protein or system described herein.

[0271] Methods for Regulating Protein Activity890564-0003-W001

[0272] FIG. 4 illustrates a flowchart of a method 100 for regulating activity of a protein. The method 100 includes a step 102 and a step 104.

[0273] In the step 102, a protein is provided. The protein comprises a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein. In the protein, the first portion of the parent protein is C-terminal or N-terminal to the second portion of the parent protein. In some cases, the first portion of the parent protein may be C-terminal to the second portion of the parent protein in the protein. In some aspects, the first portion of the parent protein may be N-terminal to the second portion of the parent protein in the protein.

[0274] The sequence of amino acid residues disrupts an interaction between at least two amino acid residues of the protein. The disruption of the interaction between the at least two amino acid residues may affect the activity of the protein. As described above, the at least two amino acid residues may comprise a hydrophobic cluster in the parent protein. The sequence of amino acid residues may prevent proper contact between amino acid residues that contribute to the three-dimensional structure of the protein.

[0275] In some aspects, the parent protein may be a fluorescent protein. The fluorescent protein may be a superfolder variant of green fluorescent protein. The superfolder variant of green fluorescent protein may comprise one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. When the parent protein is a fluorescent protein, disruption of the interaction between the at least two amino acid residues may result in decreased fluorescence of the protein.

[0276] In the step 104, the protein is contacted with the protease to cleave the sequence of amino acid residues. Cleavage of the sequence of amino acid residues restores the interaction between the at least two amino acid residues. In some cases, the protease may be Tobacco Etch Virus protease. The Tobacco Etch Virus protease may recognize and cleave a sequence having the motif ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site.

[0277] When the parent protein is a fluorescent protein, restoring the interaction increases fluorescence of the protein. The increase in fluorescence may result from restoration of proper folding and chromophore formation within the fluorescent protein. In some aspects, the method 100 may further comprise detecting the increase in fluorescence and using the increase in fluorescence as an indicator of protease activity. Detection of the increase in fluorescence may890564-0003-W001

[0278] be accomplished using fluorescence microscopy, flow cytometry, microplate readers, or other fluorescence detection instruments.

[0279] Methods for Detecting Protein Secretion

[0280] FIG. 5 illustrates a flowchart of a method 200 for detecting protein secretion. The method 200 includes a step 202, a step 204, a step 206, and a step 208.

[0281] In the step 202, a fusion protein is expressed in a cell. As described above, the fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. The translocated protein domain may be configured to be transported or exported from one cellular compartment to another or from the cell. In some cases, the translocated protein domain may comprise a signal peptide. The signal peptide may mediate translocation of at least a portion of the translocated protein domain across a membrane.

[0282] In some aspects, the membrane association domain may comprise a transmembrane domain. The transmembrane domain may be a single-pass transmembrane domain. The membrane association domain may be capable of associating with or linking to a cellular membrane such as a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane.

[0283] In the step 204, a membrane-localized protein comprising an enzymatic domain is expressed in the cell. As described above, the membrane-localized protein may be localized to a plasma membrane through S-palmitoylation or myristoylation. The enzymatic domain may be configured to modulate the post-translational modification site of the fusion protein.

[0284] In the step 206, the enzymatic domain is allowed to modulate the post-translational modification site of the fusion protein. In some aspects, the post-translational modification site may comprise a protease cleavage site, and modulating the post-translational modification site may comprise cleaving the fusion protein at the protease cleavage site. Cleavage of the fusion protein may separate the translocated protein domain from the indicator domain. In some cases, the enzymatic domain may comprise a Tobacco Etch Virus protease, and the post-translational modification site may comprise a Tobacco Etch Virus protease cleavage site having the sequence ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site.

[0285] In some cases, modulating the post-translational modification site may comprise phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein. Modulation of the post-translational modification site may occur when the fusion890564-0003-W001

[0286] protein reaches a subcellular compartment or plasma membrane where the membrane-localized protein is localized.

[0287] In the step 208, a change in a characteristic conferred by the indicator domain is detected. In some aspects, the indicator domain may comprise a fluorescent protein, and detecting the change may comprise detecting a change in fluorescence. The change in fluorescence may indicate that the translocated protein domain has been transported to a subcellular compartment or plasma membrane where the enzymatic domain is localized. In some cases, the indicator domain may remain a constituent of the cell after export of the translocated protein domain, allowing for detection of protein secretion events.

[0288] In some aspects, detection of the change in the characteristic conferred by the indicator domain may be accomplished using confocal microscopy. Confocal microscopy may be used to demonstrate that the system may be used to detect cellular protein secretion. In some cases, detection may be accomplished using fluorescence microscopy, flow cytometry, microplate readers, or other fluorescence detection instruments.

[0289] In some aspects, the cell may be a prokaryotic cell or a eukaryotic cell. In some cases, the cell may be an Escherichia coli cell. In some cases, the cell may be a Saccharomyces cerevisiae cell. In some cases, the cell may be a Schizosaccharomyces pombe cell. In some cases, the cell may be a Pichia pastoris cell. In some cases, the cell may be a Yarrowia lipolytica cell. In some cases, the cell may be a Chinese hamster ovary cell. In some cases, the cell may be a murine myeloma cell. In some cases, the cell may be a human embryonic kidney cell.

[0290] Functional Interactions

[0291] In some aspects, the elements of an engineered protein may interact to provide protease-regulated activity. In an engineered protein comprising a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease, the sequence of amino acid residues may disrupt an interaction between at least two amino acid residues of the engineered protein. The disruption of the interaction between the at least two amino acid residues may affect the folding or activity of the engineered protein. In some cases, when the parent protein is a fluorescent protein, the disruption of the interaction may result in decreased fluorescence of the engineered protein.

[0292] In some cases, the sequence of amino acid residues recognized by the protease may be positioned at or near a terminus of the engineered protein. The sequence of amino acid residues may prevent proper contact between amino acid residues that contribute to the three-dimensional structure of the engineered protein. In some aspects, the amino acid residues disrupted by the890564-0003-W001

[0293] sequence of amino acid residues may comprise a hydrophobic cluster in the parent protein. The hydrophobic cluster may comprise amino acid residues that contribute to folding of the engineered protein. For example, in a circularly permutated superfolder green fluorescent protein, amino acid residues 1152 and 1161 may be part of a hydrophobic cluster of amino acid residues that contribute to folding of the protein. The sequence of amino acid residues recognized by the protease may disrupt an interaction between 1152 and an amino acid residue interacting with 1152, or an interaction between 1161 and an amino acid residue interacting with 1161.

[0294] In some aspects, upon cleavage of the sequence of amino acid residues by the protease, the interaction between the at least two amino acid residues may be restored. Restoration of the interaction may allow the engineered protein to adopt a conformation that supports activity. In some cases, when the parent protein is a fluorescent protein, cleavage of the sequence of amino acid residues may restore the interaction between the at least two amino acid residues and increase fluorescence of the engineered protein. The increase in fluorescence may be detected and used as an indicator of protease activity.

[0295] In some aspects, the elements of a fusion protein-based system may interact to detect protein secretion. A fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. A membrane-localized protein may comprise an enzymatic domain configured to modulate the post-translational modification site of the fusion protein. The interaction between the enzymatic domain of the membrane-localized protein and the post-translational modification site of the fusion protein may occur when the fusion protein is transported to a subcellular compartment or plasma membrane where the membrane-localized protein is localized.

[0296] In some cases, the translocated protein domain of the fusion protein may comprise a signal peptide. The signal peptide may mediate translocation of at least a portion of the translocated protein domain across a membrane. As the fusion protein is transported through the secretory pathway, the membrane association domain may associate with or link to a cellular membrane such as a membrane of the endoplasmic reticulum, a membrane of the Golgi apparatus, a vacuole membrane, or a plasma membrane.

[0297] In some aspects, when the fusion protein reaches a subcellular compartment or plasma membrane where the membrane-localized protein is localized, the enzymatic domain of the membrane-localized protein may modulate the post-translational modification site of the fusion protein. In some cases, the post-translational modification site may comprise a protease cleavage site, and modulation may comprise cleavage of the fusion protein at the protease cleavage site. Cleavage of the fusion protein may separate the translocated protein domain from the indicator890564-0003-W001

[0298] domain. In some aspects, the enzymatic domain may comprise a Tobacco Etch Virus protease, and the post-translational modification site may comprise a Tobacco Etch Virus protease cleavage site having the sequence ENLYFQ / X (SEQ ID NO: 17), where x represents the amino acid residue following the cleavage site.

[0299] In some cases, modulation of the post-translational modification site may result in a detectable change in a characteristic conferred by the indicator domain. In some aspects, the indicator domain may comprise a fluorescent protein, and detection of protein secretion may comprise detecting a change in fluorescence. The change in fluorescence may indicate that the translocated protein domain has been transported to a subcellular compartment or plasma membrane where the enzymatic domain is localized. In some cases, the indicator domain may remain a constituent of a cell after export of the translocated protein domain, allowing for detection of protein secretion events.

[0300] In some aspects, the membrane-localized protein may be localized to a plasma membrane through S-palmitoylation or myristoylation. S-palmitoylation and myristoylation are lipid modifications that may anchor the membrane-localized protein to the plasma membrane. When the fusion protein reaches the plasma membrane during secretion, the enzymatic domain of the membrane-localized protein may modulate the post-translational modification site of the fusion protein, resulting in a detectable change in the indicator domain that indicates protein secretion has occurred.

[0301] Experimental Examples

[0302] In some aspects, cells may be modified to isolate and expand clonal populations of cells that include a fusion protein or system described herein. The following examples illustrate experimental validation of the protease biosensor in Escherichia coli cells.

[0303] FIG. 2 depicts an SDS-PAGE gel image showing a soluble fraction from whole cell lysates of eight different cultures of E. coli. The eight cultures represent four different cell types, each grown under two different conditions. Wild type cells comprise no plasmids. TEV cells comprise a plasmid corresponding to SEQ ID NO: 3. Biosensor cells comprise a plasmid corresponding to SEQ ID NO: 9. TEV plus Biosensor cells comprise plasmids corresponding to both SEQ ID NO: 9 and SEQ ID NO: 3.

[0304] In some aspects, cells may be grown in LB with approximately 0.4% arabinose w / v to induce expression from an arabinose-inducible promoter. In FIG. 2, a plus sign indicates that the culture was grown in LB with approximately 0.4% arabinose w / v, while a minus sign indicates the culture was grown in LB without arabinose. The plasmid corresponding to SEQ ID NO: 9890564-0003-W001

[0305] comprises an arabinose-inducible promoter and may be used to express the biosensor encoded by SEQ ID NO: 9.

[0306] In some cases, leaky expression from a tetracycline-inducible promoter may express enough TEV protease to cleave the biosensor without requiring anhydrotetracycline induction. The plasmid corresponding to SEQ ID NO: 3 comprises a tetracycline-inducible promoter. Leaky expression from the tetracycline-inducible promoter of SEQ ID NO: 3 may express sufficient TEV protease to cleave the biosensor, and therefore no anhydrotetracycline may be used to induce expression of the TEV protease.

[0307] In FIG. 2, arrows indicate bands where the biosensor migrated or where one of the two cleavage fragments of the biosensor migrated after the biosensor was cleaved by TEV protease. The uppermost arrow points to the Biosensor band, the middle arrow points to Fragment 1, and the lowest arrow points to Fragment 2. Fragment 1 and Fragment 2 represent cleavage products of the biosensor after cleavage by TEV protease.

[0308] In some aspects, cells may be lysed using NEBExpress E. coli Lysis Reagent and the supernatant run on an SDS-PAGE gel stained with Bio-Safe Coomassie Stain. In the experiments shown in FIG. 2, cell pellets were resuspended in NEBExpress E. coli Lysis Reagent. The cells were gently vortexed for 20 minutes to lyse the cells and the supernatant was cleared by centrifugation. About 20 µL of the supernatant was run on an SDS-PAGE gel and stained with Bio-Safe Coomassie Stain.

[0309] FIG. 3 depicts a bar graph showing mean relative fluorescence units (RFU) by well for eight different cultures of E. coli measured on a microplate reader. The y-axis displays relative fluorescence units, while the x-axis shows four experimental conditions: Wild Type, TEV, Biosensor, and TEV plus Biosensor. Each condition includes two bars representing uninduced (light gray) and induced (dark gray) cultures. Induced cultures were grown in LB with approximately 0.4% arabinose w / v, and uninduced cultures were grown in LB without arabinose.

[0310] In some aspects, the fluorescence of cells may be measured on a microplate reader by scanning 21 points per well and averaging the relative fluorescence units. In the experiments shown in FIG. 3, the fluorescence measurements were obtained by scanning the area of each well and collecting data from 21 points, which was then averaged. The excitation wavelength was 485 nm and the emission wavelength was 535 nm.

[0311] As shown in FIG. 3, wild type cells comprising no plasmids show minimal fluorescence in both uninduced and induced conditions. TEV cells comprising a plasmid corresponding to SEQ ID NO: 3 display similarly low fluorescence levels. Biosensor cells comprising a plasmid corresponding to SEQ ID NO: 9 exhibit low fluorescence comparable to the wild type and TEV890564-0003-W001

[0312] conditions. TEV plus Biosensor cells comprising plasmids corresponding to both SEQ ID NO: 9 and SEQ ID NO: 3 show a substantial increase in fluorescence in the induced condition, while the uninduced condition remains at a low level similar to the other experimental groups. The increase in fluorescence in the induced TEV plus Biosensor cells demonstrates that cleavage of the biosensor by TEV protease restores fluorescence of the circularly permutated superfolder green fluorescent protein.

[0313] Summary of Embodiments

[0314] In some aspects, the present disclosure provides engineered proteins comprising circularly permutated variants of parent proteins, where the linear arrangement of amino acid residues differs from the parent protein while the overall three-dimensional structure may be preserved. The engineered proteins may comprise a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The sequence of amino acid residues may disrupt an interaction between amino acid residues within the engineered protein, thereby affecting the activity of the engineered protein. Upon cleavage of the sequence of amino acid residues by the protease, the interaction between the amino acid residues may be restored, and the activity of the engineered protein may be modulated.

[0315] In some cases, the parent protein may be a fluorescent protein such as green fluorescent protein or a superfolder variant thereof. The superfolder variant of green fluorescent protein may comprise one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. When the parent protein is a fluorescent protein, disruption of the interaction between amino acid residues may result in decreased fluorescence of the protein, and cleavage of the sequence of amino acid residues may increase fluorescence of the engineered protein.

[0316] In some aspects, the present disclosure provides fusion protein-based systems for regulating activity of a protein. A fusion protein may comprise a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. The translocated protein domain may comprise a signal peptide configured to mediate translocation of at least a portion of the translocated protein domain across a membrane. The membrane association domain may comprise a transmembrane domain capable of associating with or linking to a cellular membrane. The post-translational modification site may comprise a protease cleavage site, a phosphorylation site, a glycosylation site, or a SUMOylation site. The indicator domain may comprise a fluorescent protein, a split fluorescent protein, a Forster890564-0003-W001

[0317] resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing protein.

[0318] In some cases, a system for regulating activity of a protein may comprise a fusion protein and a membrane-localized protein. The membrane-localized protein may comprise an enzymatic domain configured to modulate the post-translational modification site of the fusion protein. The membrane-localized protein may be localized to a plasma membrane through S-palmitoylation or myristoylation. The enzymatic domain may comprise a Tobacco Etch Virus protease, a kinase, a SUMO-protein, or a glycosylation enzyme. Modulation of the post-translational modification site may comprise cleavage of the fusion protein, phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein.

[0319] In some aspects, the present disclosure provides methods for regulating activity of a protein. A method may comprise providing a protein comprising a first portion of a parent protein, a second portion of the parent protein, and a sequence of amino acid residues configured to be recognized by a protease. The sequence of amino acid residues may disrupt an interaction between at least two amino acid residues of the protein. The method may further comprise contacting the protein with the protease to cleave the sequence of amino acid residues, thereby restoring the interaction between the at least two amino acid residues. When the parent protein is a fluorescent protein, restoring the interaction may increase fluorescence of the protein.

[0320] In some aspects, the present disclosure provides methods for detecting protein secretion. A method may comprise expressing in a cell a fusion protein comprising a translocated protein domain, a membrane association domain, a post-translational modification site, and an indicator domain. The method may further comprise expressing in the cell a membrane-localized protein comprising an enzymatic domain. The method may further comprise allowing the enzymatic domain to modulate the post-translational modification site of the fusion protein. The method may further comprise detecting a change in a characteristic conferred by the indicator domain. The cell may be an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, or a human embryonic kidney cell.

[0321] In some cases, the present disclosure provides polynucleotides encoding the proteins and fusion proteins described herein. The present disclosure also provides cells comprising the polynucleotides or systems described herein.

[0322] One embodiment described herein is an engineered protein, comprising a first portion of a parent protein a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein; and a protease890564-0003-W001

[0323] recognition sequence wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein. In one aspect, the second portion of the parent protein is operably linked to the N-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence is operably linked to the N-terminus of the second portion of the parent protein. In another aspect, the protease recognition sequence is directly fused to the N-terminus of the second portion of the parent protein. In another aspect, the protease recognition sequence is operably linked to the C-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence is directly fused to the C-terminus of the first portion of the parent protein. In another aspect, the protease recognition sequence destabilizes at least one intramolecular interaction of the engineered protein, such that proteolytic cleavage of the protease recognition sequence at least partially stabilizes the destabilized intramolecular interaction. In another aspect, the intramolecular interaction is a hydrophobic interaction between at least two amino acid residues that form part of a hydrophobic cluster in the parent protein. In another aspect, the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1152. In another aspect, the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1161. In another aspect, the protease recognition sequence reduces activity of the engineered protein relative to the parent protein. In another aspect, proteolytic cleavage of the protease recognition sequence increases biological activity of the engineered protein. In another aspect, proteolytic cleavage of the protease recognition sequence restores the engineered protein to an active conformation. In another aspect, the parent protein is selected from an enzyme, a fluorescent protein, a transcription factor, or a receptor. In another aspect, the parent protein is a fluorescent protein. In another aspect, the fluorescent protein is a superfolder variant of green fluorescent protein. In another aspect, the superfolder variant of green fluorescent protein comprises one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. In another aspect, the protease recognition sequence is cleavable by a protease selected from TEV protease, Thrombin, caspase, Factor Xa, SUMO Protease, Trypsin, Enterokinase, or Endoproteinase AspN. In another aspect, the protease recognition sequence is configured to be recognized by Tobacco Etch Virus protease. In another aspect, the protease recognition sequence comprises ENLYFQ / X (SEQ ID NO: 17), where X represents an amino acid residue following a cleavage site. In another aspect, at least a portion of a beta sheet near a C-terminus of the first portion of the parent protein is sequentially890564-0003-W001

[0324] last to fold. In another aspect, the protein comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 8, 10, 12, 14, or 16. In another aspect, the protein comprises an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 16. In another aspect, the protein is expressed by a nucleotide sequence having at least 90-99% identity to SEQ ID NO: 7, 9, 11, 13, or 15. In another aspect, the protein is expressed by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

[0325] Another embodiment described herein is a method for regulating activity of a protein, comprising providing a protein comprising a first portion of a parent protein a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein a protease recognition sequence wherein the sequence of amino acid residues disrupts an interaction between at least two amino acid residues of the protein; and contacting the protein with the protease to cleave the protease recognition sequence, thereby restoring the interaction between the at least two amino acid residues. In one aspect, the first portion of the parent protein is C-terminal to the second portion of the parent protein in the protein. In another aspect, the first portion of the parent protein is N-terminal to the second portion of the parent protein in the protein. In another aspect, the parent protein is a fluorescent protein, and wherein restoring the interaction increases fluorescence of the protein. In another aspect, the fluorescent protein is a superfolder variant of green fluorescent protein comprising one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V. In another aspect, the protease is Tobacco Etch Virus protease.

[0326] Another embodiment described herein is a fusion protein, comprising a translocated protein domain a membrane association domain a post-translational modification site; and a biosensor. In one aspect, translocated protein domain comprises a signal peptide. In another aspect, signal peptide is positioned at an N-terminus of the fusion protein. In another aspect, membrane association domain comprises a transmembrane domain. In another aspect, transmembrane domain is a single-pass transmembrane domain. In another aspect, post-translational modification site comprises a protease cleavage site. In another aspect, protease cleavage site comprises a Tobacco Etch Virus protease cleavage site. In another aspect, post-translational modification site comprises a phosphorylation site, a glycosylation site, or a SUMOylation site. In another aspect, biosensor comprises a split fluorescent protein, a Förster resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing890564-0003-W001

[0327] protein. In another aspect, biosensor comprises a fluorescent protein. In another aspect, translocated protein domain comprises a carbohydrase, an alpha-amylase, a protease, a subtilisin, insulin, beta-lactoglobulin, ovalbumin, albumin, an antibody, ora single-chain antibody fragment. In another aspect, fusion protein comprises an amino acid sequence having at least 95-99% identity to SEQ ID NO: 8 or comprises an amino acid sequence of SEQ ID NO: 8. In another aspect, fusion protein is expressed by a nucleotide sequence having at least 95-99% identity to SEQ ID NO: 7 or a nucleotide sequence comprising SEQ ID NO: 7.

[0328] Another embodiment described herein is a system for regulating activity of a protein comprising a fusion protein comprising a translocated protein domain a membrane association domain a post-translational modification site; and a biosensor; and a membrane-localized protein comprising an enzymatic domain configured to modulate the post-translational modification site of the fusion protein. In one aspect, the membrane-localized protein is localized to a plasma membrane through S-palmitoylation or myristoylation. In another aspect, the enzymatic domain comprises a Tobacco Etch Virus protease. In another aspect, the enzymatic domain comprises a kinase, a SUMO-protein, or a glycosylation enzyme. In another aspect, modulation of the post-translational modification site comprises cleavage of the fusion protein, phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein. In another aspect, the biosensor comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 10.

[0329] Another embodiment described herein is a method for regulating activity of a protein, comprising expressing in a cell a fusion protein comprising a translocated protein domain, a membrane association domain, a post-translational modification site, and an biosensor expressing in the cell a membrane-localized protein comprising an enzymatic domain allowing the enzymatic domain to modulate the post-translational modification site of the fusion protein; and detecting a change in a characteristic conferred by the biosensor. In one aspect, the post-translational modification site comprises a protease cleavage site, and wherein modulating the post-translational modification site comprises cleaving the fusion protein at the protease cleavage site. In another aspect, the biosensor comprises a fluorescent protein, and wherein detecting the change comprises detecting a change in fluorescence. In another aspect, the cell is an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, or a human embryonic kidney cell.

[0330] Another embodiment described herein is a nucleic acid molecule encoding the biosensors described herein or the fusion proteins described herein.890564-0003-W001

[0331] Another embodiment described herein is a vector comprising the nucleic acid molecules described herein.

[0332] Another embodiment described herein is a cell comprising the system described herein, the nucleic acid molecules described herein, or the vectors described herein.

[0333] Another embodiment described herein is a use of the proteins described herein; the methods described herein, the fusion proteins described herein; or the systems described herein for regulating protein function.

[0334] It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the foregoing discussion discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.

[0335] Various embodiments and aspects of the inventions described herein are summarized by the following clauses:

[0336] Clause 1. An engineered protein, comprising:

[0337] a first portion of a parent protein;

[0338] a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein; and a protease recognition sequence;

[0339] wherein, in the engineered protein, the second portion of the parent protein is located N- terminal to the first portion of the parent protein, and890564-0003-W001

[0340] wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein. Clause 2. The engineered protein of clause 1, wherein the second portion of the parent protein is operably linked to the N-terminus of the first portion of the parent protein.

[0341] Clause 3. The engineered protein of clause 1 or 2, wherein the protease recognition sequence is operably linked to the N-terminus of the second portion of the parent protein. Clause 4. The engineered protein of any one of clauses 1-3, wherein the protease recognition sequence is directly fused to the N-terminus of the second portion of the parent protein.

[0342] Clause 5. The engineered protein of any one of clauses 1-4, wherein the protease recognition sequence is operably linked to the C-terminus of the first portion of the parent protein.

[0343] Clause 6. The engineered protein of any one of clauses 1-5, wherein the protease recognition sequence is directly fused to the C-terminus of the first portion of the parent protein.

[0344] Clause 7. The engineered protein of any one of clauses 1-6, wherein the protease recognition sequence destabilizes at least one intramolecular interaction of the engineered protein, such that proteolytic cleavage of the protease recognition sequence at least partially stabilizes the destabilized intramolecular interaction.

[0345] Clause 8. The engineered protein of any one of clauses 1-7, wherein the intramolecular interaction is a hydrophobic interaction between at least two amino acid residues that form part of a hydrophobic cluster in the parent protein.

[0346] Clause 9. The engineered protein of any one of clauses 1-8, wherein the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1152.

[0347] Clause 10. The engineered protein of any one of clauses 1-9, wherein the parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1161.

[0348] Clause 11. The engineered protein of any one of clauses 1-10, wherein the protease recognition sequence reduces activity of the engineered protein relative to the parent protein.

[0349] Clause 12. The engineered protein of any one of clauses 1-11, wherein proteolytic cleavage of the protease recognition sequence increases biological activity of the engineered protein.890564-0003-W001

[0350] Clause 13. The engineered protein of any one of clauses 1-12, wherein proteolytic cleavage of the protease recognition sequence restores the engineered protein to an active conformation.

[0351] Clause 14. The engineered protein of any one of clauses 1-13, wherein the parent protein is selected from an enzyme, a fluorescent protein, a transcription factor, or a receptor. Clause 15. The engineered protein of any one of clauses 1-14, wherein the parent protein is a fluorescent protein.

[0352] Clause 16. The engineered protein of any one of clauses 1-15, wherein the fluorescent protein is a superfolder variant of green fluorescent protein.

[0353] Clause 17. The engineered protein of any one of clauses 1-16, wherein the superfolder variant of green fluorescent protein comprises one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V.

[0354] Clause 18. The engineered protein of any one of clauses 1-17, wherein the protease recognition sequence is cleavable by a protease selected from TEV protease, Thrombin, caspase, Factor Xa, SUMO Protease, Trypsin, Enterokinase, or Endoproteinase AspN. Clause 19. The engineered protein of any one of clauses 1-18, wherein the protease recognition sequence is configured to be recognized by Tobacco Etch Virus protease. Clause 20. The engineered protein of any one of clauses 1-19, wherein the protease recognition sequence comprises ENLYFQ / X (SEQ ID NO: 17), where X represents an amino acid residue following a cleavage site.

[0355] Clause 21. The engineered protein of any one of clauses 1-20, wherein at least a portion of a beta sheet near a C-terminus of the first portion of the parent protein is sequentially last to fold.

[0356] Clause 22. The engineered protein of any one of clauses 1-21, wherein the protein comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 8, 10, 12, 14, or 16.

[0357] Clause 23. The engineered protein of any one of clauses 1-22, wherein the protein comprises an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 16.

[0358] Clause 24. The engineered protein of any one of clauses 1-23, wherein the protein is expressed by a nucleotide sequence having at least 90-99% identity to SEQ ID NO: 7, 9, 11, 13, or 15.

[0359] Clause 25. The engineered protein of any one of clauses 1-24, wherein the protein is expressed by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

[0360] Clause 26. A method for regulating activity of a protein, comprising:890564-0003-W001

[0361] providing a protein comprising:

[0362] a first portion of a parent protein;

[0363] a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein;

[0364] wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein;

[0365] a protease recognition sequence wherein the sequence of amino acid residues disrupts an interaction between at least two amino acid residues of the protein; and

[0366] contacting the protein with the protease to cleave the protease recognition sequence, thereby restoring the interaction between the at least two amino acid residues. Clause 27. The method of clause 26, wherein the first portion of the parent protein is C- terminal to the second portion of the parent protein in the protein.

[0367] Clause 28. The method of clause 26 or 27, wherein the first portion of the parent protein is N- terminal to the second portion of the parent protein in the protein.

[0368] Clause 29. The method of any one of clauses 26-28, wherein the parent protein is a fluorescent protein, and wherein restoring the interaction increases fluorescence of the protein.

[0369] Clause 30. The method of any one of clauses 26-29, wherein the fluorescent protein is a superfolder variant of green fluorescent protein comprising one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, and A206V.

[0370] Clause 31. The method of any one of clauses 26-30, wherein the protease is Tobacco Etch Virus protease.

[0371] Clause 32. A fusion protein, comprising:

[0372] a translocated protein domain;

[0373] a membrane association domain;

[0374] a post-translational modification site; and

[0375] a biosensor.

[0376] Clause 33. The fusion protein of clause 32, wherein the translocated protein domain comprises a signal peptide.890564-0003-W001

[0377] Clause 34. The fusion protein of clause 32 or 33, wherein the signal peptide is positioned at an N-terminus of the fusion protein.

[0378] Clause 35. The fusion protein of any one of clauses 32-34, wherein the membrane association domain comprises a transmembrane domain.

[0379] Clause 36. The fusion protein of any one of clauses 32-35, wherein the transmembrane domain is a single-pass transmembrane domain.

[0380] Clause 37. The fusion protein of any one of clauses 32-36, wherein the post-translational modification site comprises a protease cleavage site.

[0381] Clause 38. The fusion protein of any one of clauses 32-37, wherein the protease cleavage site comprises a Tobacco Etch Virus protease cleavage site.

[0382] Clause 39. The fusion protein of any one of clauses 32-38, wherein the post-translational modification site comprises a phosphorylation site, a glycosylation site, or a SUMOylation site.

[0383] Clause 40. The fusion protein of any one of clauses 32-39, wherein the biosensor comprises a split fluorescent protein, a Förster resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing protein.

[0384] Clause 41. The fusion protein of any one of clauses 32-40, wherein the biosensor comprises a fluorescent protein.

[0385] Clause 42. The fusion protein of any one of clauses 32-41, wherein the translocated protein domain comprises a carbohydrase, an alpha-amylase, a protease, a subtilisin, insulin, beta-lactoglobulin, ovalbumin, albumin, an antibody, or a single-chain antibody fragment. Clause 43. The fusion protein of any one of clauses 32-42, wherein the fusion protein comprises an amino acid sequence having at least 95-99% identity to SEQ ID NO: 8 or comprises an amino acid sequence of SEQ ID NO: 8.

[0386] Clause 44. The fusion protein of any one of clauses 32-43, wherein the fusion protein is expressed by a nucleotide sequence having at least 95-99% identity to SEQ ID NO: 7 or a nucleotide sequence comprising SEQ ID NO: 7.

[0387] Clause 45. A system for regulating activity of a protein comprising:

[0388] a fusion protein comprising:

[0389] a translocated protein domain;

[0390] a membrane association domain;

[0391] a post-translational modification site; and

[0392] a biosensor; and890564-0003-W001

[0393] a membrane-localized protein comprising an enzymatic domain configured to modulate the post-translational modification site of the fusion protein. Clause 46. The system of clause 45, wherein the membrane-localized protein is localized to a plasma membrane through S-palmitoylation or myristoylation.

[0394] Clause 47. The system of clause 45 or 46, wherein the enzymatic domain comprises a Tobacco Etch Virus protease.

[0395] Clause 48. The system of any one of clauses 45-47, wherein the enzymatic domain comprises a kinase, a SUMO-protein, or a glycosylation enzyme.

[0396] Clause 49. The system of any one of clauses 45-48, wherein modulation of the post- translational modification site comprises cleavage of the fusion protein, phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein.

[0397] Clause 50. The system of any one of clauses 45-49, wherein the biosensor comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 10.

[0398] Clause 51. A method for regulating activity of a protein, comprising:

[0399] expressing in a cell a fusion protein comprising a translocated protein domain, a membrane association domain, a post-translational modification site, and an biosensor;

[0400] expressing in the cell a membrane-localized protein comprising an enzymatic domain; allowing the enzymatic domain to modulate the post-translational modification site of the fusion protein; and

[0401] detecting a change in a characteristic conferred by the biosensor.

[0402] Clause 52. The method of clause 51, wherein the post-translational modification site comprises a protease cleavage site, and wherein modulating the post-translational modification site comprises cleaving the fusion protein at the protease cleavage site. Clause 53. The method of clause 51 or 52, wherein the biosensor comprises a fluorescent protein, and wherein detecting the change comprises detecting a change in fluorescence. Clause 54. The method of any one of clauses 51-53, wherein the cell is an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, or a human embryonic kidney cell.

[0403] Clause 55. A nucleic acid molecule encoding the biosensor of any one of clauses 1-25 or the fusion protein of any one of clauses 32-44.

[0404] Clause 56. A vector comprising the nucleic acid molecule of clause 55.890564-0003-W001

[0405] Clause 57. A cell comprising the system of any one of clauses 45-50, the nucleic acid molecule of clause 55, or the vector of clause 56.

[0406] Clause 58. Use of the protein of any one of clauses 1-25; the method of any one of clauses 26-31, the fusion protein of any one of clauses 32-44; or the system of any one of clauses 45-50 for regulating protein function.

[0407] EXAMPLES

[0408] Example 1

[0409] Genetically encoded biosensors that incorporate fluorescent proteins such as green fluorescent protein (GFP) are able to detect chemical signals such as calcium ions, pH, or small molecules like glucose by converting them into measurable fluorescent signals. Many of these sensors change conformation when a domain of the biosensor interacts with the chemical signal and causes a change in the fluorescent signal. These biosensors have been crucial for understanding biological processes such as the visualization of calcium signaling of individual neurons in the brain.

[0410] In addition to detecting chemical signals, biosensors can also be used to detect biological activity such as protease activity. Most protease biosensors are based on splitting GFP into two non-fluorescent fragments that can reassemble and catalyze the formation of a chromophore that can produce a fluorescent signal. By adding protein domains to at least one of the GFP fragments, reassembly can be inhibited until one of the fragments is cleaved by a protease. The challenge with these split GFP based protease biosensors is that the two halves are not completely folded, leading to problems with solubility and aggregation. Additionally, targeted degradation of the two halves can be more difficult compared to biosensors comprising a single protein.

[0411] We used a protease-based biosensor to detect subcellular localization of proteins. This could be accomplished by fusing a first half of a protease biosensor to a protein of interest operably linked to the membrane of a first cellular organelle and expressing a second half of a protease biosensor in the cytoplasm of the cell. The protease could then be operably linked to the membrane of a second cellular organelle. When the protein of interest localized from the first organelle to the second organelle, the first half of the protease biosensor could be cleaved by the protease and assemble with the second half of the protease biosensor in the cytoplasm and form a chromophore that could be measured or detected.

[0412] However, the decreased solubility of split protease biosensors can cause them to aggregate at high concentrations and expressing them on the membrane of an organelle can890564-0003-W001

[0413] increase the effective concentration compared to cytoplasmically expressed proteins. To address the challenges associated with split protease biosensors and to simplify the system, we sought to develop a single fragment protease biosensor.

[0414] We started with the superfolder GFP (sfGFP) due to its increased solubility. We then created a circular permutant of the protein that started at strand 8 and ended at strand 7 and included a linker between the original N and C termini. Next we performed truncation experiments on the N and C termini of the circularly permutated sfGFP and discovered that removal of the amino acids down to and including 1161 on strand 8 and 1152 on strand 7 resulted in a non- fluorescent protein with high solubility. These two amino acids are predicted to be part of a hydrophobic cluster of amino acid residues important to folding of the protein. We then constructed additional circularly permutated sfGFPs that incorporated a TEV protease cleavage site (ENLYFQ / X) (SEQ ID NO: 17) at different locations to determine if the amino acids of the TEV site could prevent the protein from becoming fluorescent. We found that by inserting the TEV site before N164 (ENLYFQ / N164) (SEQ ID NO: 18) and ending on A163 we could significantly reduce the fluorescence of the protein. Next, we purified this protein and incubated it with TEV protease and showed that the protease was able to access the TEV site and cleave the protein. Furthermore, after cleavage of the protein, we observed a significant increase in fluorescence.

[0415] In the Sequences shown below, the polynucleotide sequence is an odd number and the polypeptide sequence is an even number in the NT / AA pairs.

[0416] sfGFP Protein - Polynucleotide and Polypeptide Sequences (SEQ ID NO: 1-2)

[0417]

[0418] 890564-0003-W001

[0419] ctg gaa ttt gtt acc gcc gcg ggc att acc cac ggt atg gat gaa ctg tat aaa L E F V T A A G I T H G M D E L Y K _

[0420] Bolded residues show the codons and amino acids that were mutated to create mutants: S30R, Y39N, N105T, Y145F, 1171V, and A206V

[0421] Circularly Permutated sfGFP - Polynucleotide and Polypeptide Sequences (SEQ ID NO:

[0422]

[0423]

[0424] 890564-0003-W001

[0425]

[0426] Next we wanted to use the biosensor to detect when a protein was being secreted from a cell. We first created a strain of yeast expressing a TEV protease fused to a C-terminal Gaplc fragment (SEQ ID NO: 5) by integrating a linearized plasmid into the chromosome. This plasmid expresses TEV protease at low levels that is palmitoylated by palmitoyltransferase Pfa4 and thereby attached directly to the plasma membrane. We then transformed this strain with a plasmid that expresses a fusion protein comprising the Ost1 signal peptide, the pro-domain of the alpha mating factor, mTurquoise2, the single pass transmembrane domain of WSC4, and the protease biosensor TEV-N164-A163 (SEQ ID NO: 8). Confocal microscopy demonstrated that the whole system could be used to detect cellular protein secretion.

[0427] NEB® 10-beta Competent E. coli cells were purchased from New England Biolabs (Ipswich, Massachusetts, USA). Cells were made chemically competent using standard procedures. Briefly, the cells were streaked for single colonies on LB agar plates. A single colony was used to inoculate 5 mL LB and cultured overnight. The overnight culture was used to inoculate 495 mL of medium A (LB supplemented with 10 mM MgSO4·7 H2O and 0.2% glucose) and the culture was grown until the cells reached an OD600of about 0.4. The cells were placed on ice for 10 minutes and then pelleted at 1500 x g for 10 minutes at 4 °C. The media was completely removed and the cells were resuspended in 2 mL media A and combined with 10 mL of storage solution B (36% glycerol, 12% PEG (MW 7500), 12 mM MgSO4·7 H2O added to LB and sterilized through filtration). Aliquots of 100 pL were pipetted into Eppendorf tubes and frozen at -80 °C.

[0428] Chemically competent cells were transformed with a plasmid corresponding to SEQ ID NO: 9 or SEQ ID NO: 3 or both using standard methods. Briefly, chemically competent cells were thawed on ice for 10 minutes. Approximately 50 ng of plasmid DNA were added to the cells and the solution was mixed by flicking the tube about six times and placed back on ice. After incubating the cells on ice, cell were heat shocked at 42 °C for 30 seconds and placed back on ice for about 2 minutes. After the 2 minute incubation, 900 pL of room temperature NEB 10-beta / Stable Outgrowth Medium was added to the cells and cells were incubated at 37°C for 60 minutes with shaking at 250 rpm. Approximately 10-100 pL of the cells were plated onto LB agar890564-0003-W001

[0429] plates containing the appropriate antibiotic (carbenicillin at 100 pg / mL, kanamycin at 50 pg / mL) and grown overnight at 37 °C.

[0430] A single colony was picked from plates with cells harboring the plasmid corresponding to SEQ ID NO: 9 or SEQ ID NO: 3 or both and the single colonies were used to inoculate a 5 mL overnight culture with LB media and either carbenicillin, kanamycin, or both respectively. Additionally, chemically competent cells from a glycerol stock were used to inoculate a 5 mL overnight culture containing no antibiotic and these cells were considered wild type cells. About 10 µL from each of the four overnight cultures, referred to as wild type, TEV, biosensor, and biosensor plus TEV was used to inoculate two additional 5 mL cultures containing the appropriate antibiotic, one of which also contained approximately 0.4% arabinose w / v and the cells were grown at 30 °C for 8 hours. The plasmid corresponding to SEQ ID NO: 9 comprises an arabinose inducible promoter and can be used to express the biosensor encoded by SEQ ID NO: 9. The plasmid corresponding to SEQ ID NO: 3 comprises a tetracycline inducible promoter. It was found that leaky expression from the tetracycline inducible promoter of SEQ ID NO: 3 expressed enough TEV protease to cleave the biosensor and therefore no anhydrotetracycline was needed to induce expression of the TEV protease.

[0431] After the cells had grown for 8 hours, 1 mL from each of the eight cultures was centrifuged at 2000 x g for 4 minutes to pellet the cells. Cells were resuspended in 1 mL of PBS, centrifuged for the same speed and time, and resuspended in 100 pL of PBS. The cells were then added to a 96 well plate and the fluorescence of each well was measured on a SpectraMax i D3 microplate reader from Molecular Devices by scanning 21 points per well and averaging the relative fluorescence units. The data from this experiment is shown in FIG. 3. After the fluorescence of the cells was measured, 2.8 mL of culture from the 8 cultures was centrifuged and the pellets were frozen overnight. The pellets were then resuspended in 200 pL of NEBExpress® E. coli Lysis Reagent. The cells were gently vortexed for 20 minutes to lyse the cells, and the supernatant was cleared by centrifugation. About 20 pL of the supernatant was run on an SDS-PAGE gel and stained with Bio-Safe™ Coomassie Stain from Bio-Rad (Hercules, California, USA). The data from this experiment is shown in FIG. 2.

[0432] Example 2

[0433] Chemically competent cells are transformed with a plasmid corresponding to SEQ ID NO: 15 using standard methods and approximately 10-100 pL of the cells are plated onto LB agar plates containing carbenicillin at 100 pg / mL and grown overnight at 37 °C. A single colony is picked from plates with cells harboring the plasmid corresponding to SEQ ID NO: 15 is used to890564-0003-W001

[0434] inoculate a 5 mL overnight culture with LB media and carbenicillin. About 1 mL of the overnight culture is used to inoculate 500 mL LB containing carbenicillin and grown at 37 °C until the cells reach an OD600of 0.2, at which point the incubation temperature is adjusted to 18-30 °C, cells are incubated for 10 minutes, approximately 0.4% arabinose w / v is added to the culture, and cells are incubated for 4-16 hours.

[0435] The cells are lysed and the protein corresponding to SEQ ID NO: 16 is purified using standard methods. Briefly, the cells are harvested by centrifugation at 5,000 x g for 15 minutes at 4 °C and resuspended in 30 mL cold lysis buffer (200 mM NaCI,10 mM imidazole, 20 mM Tris HCI, pH 7.5, 25 °C) for Ni-NTA (nickel-nitrilotriacetic acid) purification. The cells are then sonicated for 30 minutes (5 sec on / 5 sec off) at an amplitude of 30% and centrifuged at 14,000 x g for 15 minutes at 4 °C. Approximately 2 mL of washed Ni-NTA affinity resin is added to the cleared lysate in a 50 mL conical tube and the tube is rotated for 30 minutes at 4 °C. The lysate with resin is poured into a column and washed with 50 mL cold lysis buffer in 10-20 mL increments. The protein is then eluted from the column with 10 mL elution buffer (lysis buffer with 250 mM imidazole). The eluted protein is dialyzed against Endoproteinase AspN reaction buffer (50 mM Tris HCI, 2.5 mM ZnSO4pH 8, 25 °C) and the concentration of purified protein may be adjusted to 1-10 pg.

[0436] The protein is then digested according to standard protocols. Briefly, a 50 pL digestion reaction is set up with 0.01-50 pg of the purified protein and 0.1-100 ng / pL endoproteinase AspN in Endoproteinase AspN reaction buffer and incubated at 4-37 °C for 1-18 hours. The reaction buffer may be modified to have NaCI concentrations in the range of 0-1 M, zinc concentrations in the range of 0-1 M, and a pH between 4 and 8.5. Other modifications to the reaction conditions may be tested for optimal cleavage. A control reaction without the endoproteinase AspN is also set up. The two reactions are then read on a machine capable of taking fluorescence measurements such as a plate reader.

[0437] SEQUENCES SEQ ID NO:1- sfGFP DNA (S30R, Y39N, N105T, Y145F, 1171V, andA206V) atgagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggccataaatttagc gttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggta actgccggttccg tggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgccatgatttcttt aaaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacctataaaacccgtgcggaagtt aaatttgaaggcgat ccctggtgaaccgcattgaactgaaaggt ttgattttaaagaagatggcaacattctgggtcataaa ctggaat taatttcaacagccataatgtgtat ttaccgccgataaacagaaaaatggcatcaaagcgaacttt aaatccgt cacaacgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctgccg gataatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgtt accgccgcgggcattacccacggtatggatgaactgtataaa

[0438] SEQ ID NO: 2 - sfGFP Protein (S30R, Y39N, N105T, Y145F, 1171V, and A206V) (FIG. 1A)890564-0003-W001

[0439] MSKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFF KSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFKIR HNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGMDELYK _

[0440] SEQ ID NO: 3 - Plasmid nucleotide sequence expressing a TEV protease _ ttaagacccactttcacattt agt gttt tctaatccgcatatgatcaattcaaggccgaataagaaggc ggctctgcacc ttggtgatcaaataattcgatagcttgtcgtaataatggcggcatactatcagtagtaggtgtttccctttcttctttagcgac ttgatgctcttgatcttccaatacgcaacctaaagtaaaatgccccacagcgctgagtgcatataatgcattctctagtgaaaa accttgttggcataaaaaggctaattgattttcgagagtttcatactgtttttctgtaggccgtgtacctaaatgtacttttgc tccatcgcgatgacttagtaaagcacatctaaaacttttagcgttattacgtaaaaaatcttgccagctttccccttctaaagg gcaaaagtgagtatggtgcct tctaacatctcaatggctaaggcgtcgagcaaagcccgctt ttttttacatgccaatacaa tgtaggctgctct cacctagcctctgggcgagtttacgggttgttaaaccttcgattccgacctcattaagcagctctaatgc gctgctaatcactttacttttatctaatctagacatcattaattcctaatttttgttgacactctatcattgatagagttattt taccactccctatcagtgatagagaaaagaattcaaaagatctaaagaggagaaaggatctatgggaatcgaagaaggtaaact ggtaatctggattaacggcgataaaggctataacggtctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagt caccgtt gagcat ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt at ct tctgggc acacgaccgctttggtggctacgctcaatctggcctgttggctgaaatcaccccggacaaagcgttccaggacaagctgtatcc gtttacctgggatgccgtacgttacaacggcaagctga tgct acccgatcgctg tgaagcg tatcgctgatttataacaa agatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactgaaagcgaaaggtaagagcgcgct gatgttcaacctgcaagaaccgtacttcacctggccgctgattgctgctgacgggggttatgcg tcaagtatgaaaacggcaa gtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgattaaaaacaaaca catgaatgcagacaccgatt ctccatcgcagaagctgcctttaataaaggcgaaacagcgatgaccatcaacggcccgtgggc atggtccaacatcgacaccagcaaagtgaattatggtgtaacggt ctgccgaccttcaagggtcaaccatccaaaccgttcgt tggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagt cctcgaaaacta ctgctgactga tgaaggtctggaagcggttaataaagacaaaccgctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatcc acgtattgccgccaccatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatg ccgctttctggtatgccgt gcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaagccctgaaagacgcgcagactaattcgagctcgaa caacaacaac ataaca taacaacaacctcgggatcgagggaaggggagattttgcaggtcatcatcatcatcatcatcatgg agaaagcttgttt aggggccgcgtgatt caacccgatatcgagcaccattgttcatttgacgaatgaatctgatgggcacac aaca cgttgt at ggtattggatttggtccctt catca tacaaacaagcacttgt tagaagaaataatggaacactggtggt ccaatcactacatggtgtattcaaggtcaagaacaccacgact tgcaacaacacc cattgatgggagggacatgataattat tcgcatgcctaaggatt cccaccatttcc caaaagctgaaatttagagagccacaaagggaagagcgcatagtccttgtgac aaccaacttccaaactaagagcatgtctagcatggtgtcagacactagttcgacattcccttcaggagatggcat ttctggaa gcattggattcaaaccaaggatgggcagtgtggcagtccattagtatcaactagagatgggttcattgttggtat cactcagc atcgaatttcaccaacacaaacaatt tttcacaagcgtgccgaaaaacttcatggaattgttgacaaatcaggaggcgcagca gtgggttagtggttggcgatt aatgctgactcagtat gtggggaggccataaag tt catggacaaacc gaagagccttt tcagccagt aaggaagcgactcaactcatgaatcgtcgtcgccgtcgctaaccggatccggctgctaacaaagcccgaaagga agctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggtt tttgct gaaaggaggaactat tccggattggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgc agcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggcttt ccccgtcaagctctaaatcgggggctccctttagggttccgattt gtgctttacggcacctcgaccccaaaaaacttgattag ggtgatggt cacgtagtgggccatcgccc gatagacggttt tcgccct tgacgttggagtccacgttc ttaatagtgga ctcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataaggga tttgccgatttcggcctat tggttaaaaaatgagctgatttaacaaaaa ttaacgcgaatt taacaaaatattaacgcttacaatttaggtggcacttttc ggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattcttagaaa aactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatcaataccatatttttgaaaaagccgtttctgtaat gaaggagaaaactcaccgaggcagttccat ggatggcaagatcctggtatcggtctgcgattccgactcgtccaacatcaata caacctattaatttcccctcgtcaaaaataaggttatcaagtgagaaatcaccatgagtgacgactgaatccggtgagaatggc aaaagtttatgcatttctttccagacttgt caacaggccagccattacgctcgtcatcaaaatcactcgcatcaaccaaaccg ttattcattcgtgattgcgcctgagcgagacgaaatacgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgcaac cggcgcaggaacactgccagcgcatcaacaatattttcacctgaatcaggatattcttctaatacctggaatgctgttttcccg gggatcgcagtggtgagtaaccatgcat cat caggagtacggataaaatgcttgatggtcggaagaggcataaattccgt cage cagtttagtctgaccatctcatctgtaacatcattggcaacgctacctttgccatgtttcagaaacaactctggcgcatcgggc ttcccatacaatcgatagattgtcgcacctgattgcccgacat atcgcgagccca ttatacccatataaa cagcatccatg ttggaatttaatcgcggcctagagcaagacgtttcccgttgaatatggctcataacaccccttg attactgtttatgtaagca gacagttttattgttcatgaccaaaatccc taacgtgagttt cgttccactgagcgtcagaccccgtagaaaagatcaaagg atcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgcc ggatcaagagctaccaactctttttccgaaggt actggcttcagcagagcgcagat ccaaat ctgtccttct gtgtagcc gtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccag tggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcgg cgggctgaacggggggttc gtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagcta gagaaagcgccacgcttcc cgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgc ctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcct atggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatc890564-0003-W001

[0441] ccctgattctgtggataaccgtatt ccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtc agtgagcgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcaatggtgcact ctcagtacaatctgctctgatgccgcatagttaagccagtatacactccgctatcgctacgtgactgggtcatggctgcgcccc gacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccg ggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaa gcgattcacagatgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctgataaagc gggccatgttaagggcggttttttcctgtttggtcactgatgcctccgtgt agggggatttctgttcatgggggtaatgatac cgatgaaacgagagaggatgctcacgatacgggt tact gat gatgaacatgcccggtt act ggaacgttgtgagggtaaacaac tggcggtatggatgcggcgggaccagagaaaaatcactcagggtcaatgccagcgcttcgttaatacagatgtaggtgttccac agggtagccagcagcatcctgcgatgcagatccggaacataatggtgcagggcgctgacttccgcgtttccagactttacgaaa cacggaaaccgaagaccattcatgttgttgctcaggtcgcagacgttttgcagcagcagtcgcttcacgttcgctcgcgtatcg gtgattcattctgct accagtaaggcaaccccgccagcct gccgggtcctcaacgacaggagcacgatcatgcgcacccgtg gggccgccatgccggcgataatggcctgcttctcgccgaaacgtttggtggcgggaccagtgacgaaggcttgagcgagggcgt gcaagattccgaataccgcaagcgacaggccgatcatcgtcgcgctccagcgaaagcggtcctcgccgaaaatgacccagagcg ctgccggcacctgtcctacgagttgcatgataaagaagacagtcataagtgcggcgacgatagtcatgccccgcgcccaccgga aggagctgactgggttgaaggctctcaagggcatcggtcgagatcgcatcgtggtggttaactcgacatcttggttaccgtgaa gttaccatcacggaaaaaggttatgctgctt

[0442] SEQ ID NO: 4 - TEV Protease Polypeptide _ MGIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDK AFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGY AFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFK GQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAWKDKPLGAVA1KSYEEELAKDPRIAATMENAQKGEIMPNIPQ MSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRGDFAGHHHHHHHGESLFKGPRDYNPISSTIVHL TNESDGHTTSLYGIGFGPFIITNKHLFRRNNGTLWQSLHGVFKVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQR EERIVLVTTNFQTKSMSSMVSDTSSTFPSGDGIFWKHWIQTKDGQCGSPLVSTRDGFIVGIHSASNFTNTNNYFTSVPKNFMEL LTNQEAQQWSGWRLNADSVLWGGHKVFMDKPEEPFQPVKEATQLMNRRRRR _

[0443] SEQ ID NO: 5 - Yeast Integrating plasmid expressing a TEV protease with a C-terminal Gaplc fragment aacgttcgtgctttgtgataaagtgtttcacgtcatccgacatgacttcgt gttatggactgaactgtgtggtgaggttccat gatttcttaggtccagcagatacatgtctcttcccaatttcttgttaaggttacggccaatgcttcggttgttgagcttgttac cgaataagccgtgaagtatgataataggtggtcttggcttcccttcatccccagtttttactgcatctctcttgattatgtcat atgaaaggtccagtgggacttgcttttgttgcagcacctttgctaatgaatgaaaggcacatagtgactgcttaaaaatgcagg aacttaaattattccgaatggtattttgtctcacatatattgtcccatactgtgccaagatcccggctttacccagt tcatca ttgtaccgttaccaattctcctcgt tatcacggttagtttttaaacctcggggtgacgtttactattggcgtactaatatatt cttattttcttttcttttttgttggcagtttcaagcaacacatgtactggataaccaacccccgcacgctcttggaaaaaattg agaaggcatcggacacttgctgatgagtatttcgaaaaattccatgaagatgaggccaagattgtttggaagagattgaaaaga agaagaagaaaaaaagataaaagcaaatcaaaagatctatgggtgagtctttgtttaagggtccaagagattacaacccaatct cttctactatcgttcacttgaccaatgaatctgatggtcataccactagcttgtacggtattggttttggtccattcatcatta ccaacaagcacttgttcagaagaaacaacggtactttggttgtccaatcattgcatggtgttttcaaggttaagaacactacca ccttgcaacaacatttgatcgatggtagagacatgat catcat cagaatgccaaaagactttccaccatttccacagaagttga agtttagagaaccacagagagaagaaagaatcgttttggtt ctaccaacttccagaccaagtctatgtcatctatggtttctg atacctcctctacttttccatctggtgatggtattttctggaagcactggattcaaact aggatggtcaatgtggttcaccat tggtttctactagagatggtttcatcgttggtattcattccgcttctaacttcactaacaccaacaactactttacctccgttc caaagaacttcatggaactgttgactaatcaagaggctcaacaatgggtttctggttggagattgaatgctgattctgttttgt ggggtggtcataaggtttttatggataagccagaagaaccattccagccagtaaaagaagctactcaattgatgaacagaagaa ggcgtagaggttctggatcaactagtggttccaggaattggaagcttttcatcccagcagaaaagatggacattgatacgggta gaagagaagtcgatttagatttgttgaaacaagaaattgcagaagaaaaggcaattatggccacaaagccaagatggtatagaa tctggaatttctggtgttaaatcct actcgagagtgcttttaactaagaattattagtcttttctgcttatttttt catcat a gtttagaacactttatattaacgaatagtttatgaatctatttaggttt aaaattgatacagtttt taagttactttttcaa agactcgtgctgtctattgcataatgcactggaaggggaaaaaaaaggtgcacacgcgtggctttttcttgaatttgcagtttg aaaaatgct gagcat gagacggaaat ct get cgtcagtggtgctcacactgacgaatcatgtacagat cat accgatgactgcc tggcgactcacaactaagcaagacagccggaaccagcgccggcgaacaccactgcatat tggcatatcacaacagtccaacta gtgcactgcagtacacggtttccttgaaatttttttgattcggtaatctccgaacagaaggaagaacgaaggaaggagcacaga cttagattggtatatatacgcatatgtagtgttgaagaaacatgaaattgcccagtattcttaacccaactgcacagaacaaaa acgtgcaggaaacgaagataaatcatgtcgaaagctacatataaggaacgtgctgctactcatcctagtcctgttgctgccaag ctatttaatatcatgcacgaaaagcaaacaaacttgtgtgcttcattggatgttcgtaccaccaaggaattactggagttagtt gaagcattaggtcccaaaatttgtttact aaaacacatgtggatatcttgactgatttttccatggagggcacagttaagccg ctaaaggcattatccgccaagtacaattttttactcttcgaggacagaaaatttgctgacattggtaatacagtcaaattgcag tactctgcgggtgtatacagaatagcagaatgggcagacattacgaatgcacacggtgtggtgggcccaggt ttgttagcggt ttgaagcaggcggcagaagaagtaacaaaggaacctagaggccttttgatgttagcaga ttgtcatgcaagggctccctatct actggagaatatactaagggtactgttgacattgcgaagagcgacaaagattttgttatcggctttattgctcaaagagacatg ggtggaagagatgaaggttacgattggttgattatgacacccggtgtgggtttagatgacaagggagatgcattgggtcaacag tatagaaccgtggatgatgtggtttctacaggatctgacattattattgttggaagaggactatttgcaaagggaagggatgct aaggtagagggtgaacgttacagaaaagcaggctgggaagcatatttgagaagatgcggccagcaaaactaaaaaactgt tta890564-0003-W001

[0444] taagtaaatgcatgtatactaaactcacaaattagagcttcaatttaattatatcagttattacccgagtagagcacttgaatc cactgccccgggaatctcggtcgtaatgatttctataatgacgaaaaaaaaaaaattggaaagaaaaagcttcatggcctttat aaaaaggaactatccaatacctcgccagaaccaagtaacagtattttacggggcacaaatcaagaacaataagacaggactgt aagatggacgcattgaactccaaagaacaacaagagttccaaaaagtagtggaacaaaagcaaatgaaggatttcatgcgtttg tactctaatctggtagaaagatgtttcacagactgtgtcaatgacttcacaacatcaaagctaaccaataaggaacaaacatgc atcatgaagtgctcagaaaagttcttgaagcatagcgaacgtgtagggcagcgtttccaagaacaaaacgctgccttgggacaa ggcttgggccgataaggtgtactggcgtatatatatctaattatgtatctctggtgt gcccatttt tagcat gtaaat at aaa gaccgagcggccgcgattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtat atatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccat agttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgat ccgcggga cccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatc cgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccat tgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatg atcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcact catggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaa gtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaac tttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatctt ccgctgttgagatccagttcgatgt acccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgc cgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcaggg ttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagt gccacctgtcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttc ttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatca ag gct cca ctctttttccgaaggta ctggcttcagc gagcgcagataccaaatactgttcttctagtgt gccgtagtt aggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcga taagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcac acagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagct tgagaaagcgccacgcttcccgaagg gagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggt tctttat gtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaa aaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgtt tcccctga ttctgtggataaccgtgcggccgccaatgctaaattcgagtgaaacacaggaagatcagaaaatcctcatttcatccatattaa caataatttcaaatgtttatttgcattatttgaaactaggcaagacaagcaacgaaacgtttttgaaaattttgagtattttca ataaatttgtagaggactcagat ttgaaaaaaagctacagcaattaatacttgataagaagagtattgagaagggcaacggtt catcatctcatggatctgcacatgaacaaacaccagagtcaaacgacgttgaaattgaggctactgcgccaattgatgacaat cagacgatgataacaaaccgaagtt tctgatgtagaaaaggattaaagatgctaagagatagtgatgatatttcat aataat gtaattctatatatgttaattaccttttttgcgaggcatattt tggtgaaggataagttttgaccatcaaagaaggtt atgt ggctgtggtttcagggtccataaagcccacatggataacattacccctgaattcgcatctagatggt gagccacaaacagccg gtacaagcaacgatctccaggaccatctgaatcatgcgcggatgacacgaactcacgacggcgatcacagacattaacccacag tacagacactgcgacaacgtggcaattcgtcgcaataccgtctcactgaactggccgataattgcagacg

[0445] SEQ ID NO: 6 - TEV protease polypeptide with a C-terminal Gaplc fragment _ MGESLFKGPRDYNPISSTIVHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGTLWQSLHGVFKVKNTTTLQQHLIDGRDMI IIRMPKDFPPFPQKLKFREPQREERIVLVTTNFQTKSMSSMVSDTSSTFPSGDGIFWKHWIQTKDGQCGSPLVSTRDGFIVGIH SASNFTNTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLWGGHKVFMDKPEEPFQPVKEATQLMNRRRRRGSGSTSGSRN WKLFIPAEKMDIDTGRREVDLDLLKQEIAEEKAIMATKPRWYRIWNFWC _

[0446] SEQ ID NO: 7 - Plasmid expressing a fusion protein comprising Ost1-signal-alpha-mating-pro-domain-mTurquoise2-WSC4-TEV-N164-A163 biosensor _ cggattagaagccgccgagcgggcgacagccctccgacggatgactctcctccgtgcgtcctcgtcatcaccggtcgcgttcct gaaacgcagatgtgcctcgcgccgcactgctccgaacaataaagattctacaatactagcttttatggttatgaagaggaaaaa ttggcagtaacctggccccacaaaccttcaaattaacgaatcaaattaacaaccataggatgataatgcgattagttttttagc cttatttctggggtaattaatcagcgaagcgatgatttttgatct ttaacagatat taaatggaaaagctgcataaccactt taactaatactttcaacattttcagtttgtatt cttcttattcaaatgtcataaaagtatcaacaaaaaattgttaatatacc tctatactttaacgtcaaggagaaaaaactataagatctatgaggcaggtttggttctcttggattgtgggattgttcctatgt tttttcaacgtgtcttctgctgctccagtcaacactacaacagaagatgaaacggcacaaattccggctgaagctgtcatcggt tacttagatttagaaggggatttcgatgttgctgttttgccattttccaacagcacaaataacgggttattgtttataaatact actattgccagcattgctgctaaagaagaaggggtatctttggataaaagagaggctgaagctggtagtatggtttctaaaggt gaagaattattcactggtgttgtcccaattttggttgaatt gatggtgatgttaatggtcacaaattttctgtctccggtgaa ggtgaaggtgatgct cttacggtaaattgaccttaaaatttatttgtactactggt aattgccagttccatggccaacctt gtcactactttatcttggggtgttcaatgttttgcaagatacccagatcatatgaaacaacatgactttttcaagtctgccatg ccagaaggttatgttcaagaaagaactatttttttcaaagatgacggtaactacaagaccagagctgaagtcaagtttgaaggt gat acct tagttaatagaatcgaattaaaaggtattgattttaaagaagatggtaacattttaggtcacaaattggaatacaat tatttctctgacaatgtttacatcactgctgacaaacaaaagaatggtatcaaagctaacttcaaaattagacacaacattgaa gatggtggtgttcaattagctgaccattatcaacaaaatactccaattggtgatggtccagtcttgttaccagacaaccattac ttatccactcaatct agttatccaaagatccaaacgaaaagagggaccacatggtcttgttagaatttgttactgctgctggt890564-0003-W001

[0447] attaccttgggtatggatgaattgtacaaaggatccttggaaaaaagagaggctgaggcaagttccacttccggcgggagcggg agtagcccagggaagattgctgccacgttcgtggtagttggcgtggtctgcttagtcattatctgcatcctgatctacctgatc catcactacagaaccggctccactagcggtggttccagtacgggctctggaggctctgggagtggcaccgagaacttgtacttc caaaacttcaagatcagacacaacgtcgaagatggttctgttcaattggctgatcattaccaacaaaacaccccaattggtgat ggtccagttttgttgccagataaccattacttgtctacccaatccgttttgtctaaggatccaaacgaaaaacgtgatcacatg gtcttgttggaatttgttactgctgctggtattacccatggatctggttcaacttctggttccgcttctaaaggtgaagagttg tttactggtgttgttccaatcttggttgaattggatggtgacgttaatggccataagttttctgttagaggtgaaggtgagggt gat gctactaatggtaaattgactttgaagttcatctgcaccacaggtaaattgccagttccatggccaactttggt tact act ttgacttatggtgtccagtgcttttctagatacccagatcatatgaagagacacgactttttcaaatccgctatgccagaaggt tacgttcaagaaagaaccatttccttcaaggatgacggtactt taagact gagccgaagttaagttcgaaggtgataccttg gttaacaggattgaattgaagggcatcgatttcaaagaggacggtaacattttgggtcataagttggagtacaacttcaactcc cataacgtttacatt ccgccgataagcaaaagaacggtattaaggctt accgcct actcgaggcgaatttcttatgattt tgatttttattattaaataagttataaaaaaaataagtgtatacaaattttaaagtgactcttaggttttaaaacgaaaattct tattcttgagtaactctttcctgtaggtcaggttgctttctcaggtatagcatgaggtcgctcttattgaccacacctctaccg gcatgccgagcaaatgcctgcaaatcgctccccatttcgct gagcat gagacggaaatctgctcgtcagtggtgctcacactga cgaatcatgtacagatcataccgatgactgcctggcgactcacaactaagcaagacagccggaaccagcgccggcgaacaccac tgcatat tggcatatcacaacagtccaactagtgcactgcagtacagtttagcttgcctcgtccccgccgggtcacccggcca gcgacatggaggcccagaataccctccttgacagtcttgacgtgcgcagctcaggggcatgatgt actgtcgcccgtacattt agcccatacatccccatgtataatcatttgcatccatacattttgatggccgcacggcgcgaagcaaaaattacggctcctcgc tccagacctgcgagcagggaaacgctcccctcacagacgcgttgaattgtccccacgccgcgcccctgtagagaaatataaaag gttaggatttgccactgaggttcttctttcatatacttccttttaaaatcttgctaggatacagttctcacatcacatccgaac ataaacaaaaatgggtaaggaaaagactcacgtttcgaggccgcgattaaattccaacatggatgctgatttatatgggtataa atgggctcgcgataatgtcgggcaatcaggtgcgacaatct tcgattgtatgggaagcccgatgcgccagagttgtttctgaa acatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgac catcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccggcaaaacagcattccaggtattaga agaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattg tccttttaacagcgatcgcgtatttcgtctggctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttga tgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcat agcttttgccattctcaccggattcagtcgtcac tcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgc agaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttc ttacagaaacggctttttcaaa at tggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaaagtaactgacaataaaaaga ttcttgttttcaagaacttgtcatttgtatagtttttttatattgtagttgttctattttaatcaaatgttagcgtgatttata ttttttttcgcctcgacatcatctgcccagatgcgaagttaagtgcgcagaaagtaatatcatgcgtcaatcgtatgtgaatgc tggtcgctatactggagtatcacgtgctataaaaataattataatttaaattttttaat taaatat taaattaaaaatagaa agtaaaaaaagaaattaaagaaaaaatagtttttgttttccgaagatgt aaagactct gggggatcgccaacaaatactacc ttttatcttgctcttcctgctctcaggtattaatgccgaattgtttcatcttgtctgtgtagaaaaccacacacgaaaatcctg tgattttacattttacttatcgttaatcgaatgtatatctatttaatctgcttttcttgtctaataaatatatatgtaaagtac gctttttgttgaaattttttaaacctttgtttatttttttttcttcattccgtaactcttctaccttctttatttactttctaa aatccaaatacaaaacataaaaataaataaacacagagtaaattcccaaattattccatcattaaaagatacgaggcgcgtgta agttacaggcaagcgatccgtcccgagcggccgcgattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatc tgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagt gctgcaatgataccgcgggacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcaga agtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagct gagtaagtagttcgccagttaatagt ttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaa cgatcaaggcgagtt catgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaag ttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtg actggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataat accgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctg ttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatctttt ctttcaccagcgtttctgggtgagca aaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatat tattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccg cgcacatttccccgaaaagtgccacctgtcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgt gaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcg gtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtt cttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttacca gtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggc tgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagct tgagaa agcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagctt ccagggggaaacgcctggtatcttt tagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtca ggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttc tttcctgcgttatcccctgattctgtggataaccgtgcggccgcccctgaattcgcatctagatggtagagccacaaacagccg gtacaagcaacgatctccaggaccatctgaatcatgcgcggatgacacgaactcacgacggcgatcacagacattaacccacag890564-0003-W001

[0448] tacagacactgcgacaacgtggcaattcgtcgcaataccgtctcactgaactggccgataattgcagacgaacgccccattatc ttagcctaaaaaaaccttctctttggaactttcagtaatacgcttaactgctcattgctatattgaagta

[0449] SEQ ID NO: 8 - Fusion Protein comprising Ost1-signal-alpha-mating-pro-domain-mTurquoise2-WSC4-TEV-N164-A163 biosensor _ MRQVWFSWIVGLFLCFFNVSSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVS LDKREAEAGSMVSKGEELFTGWPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFAR YPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQ KNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKGSL EKREAEASSTSGGSGSSPGKIAATFWVGWCLVIICILIYLIHHYRTGSTSGGSSTGSGGSGSGTENLYFQNFKIRHNVEDGS VQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGSGSTSGSASKGEELFTGWPILVELDG DVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG TYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA _

[0450] SEQ ID NO: 9 - Plasmid expressing a TEV-N164-A163 biosensor _ ttatgacaacttgacggctacatcattcactttttcttcacaaccggcacggaactcgctcgggctggccccggtgcatttttt aaatacccgcgagaaatagagttgatcgtcaaaaccaacattgcgaccgacggtggcgataggcatccgggtggtgctcaaaag cagcttcgcctggctgatacgttggtcctcgcgccagcttaagacgctaatccctaactgctggcggaaaagatgtgacagacg cgacggcgacaagcaaacatgctgtgcgacgctggcgatatcaaaattgctgtctgccaggtgatcgctgatgtactgacaagc ctcgcgt cccgatt tccatcggtggatggagcgactcgttaatcgcttccatgcgccgcagtaacaattgctcaagcagatt t tcgccagcagctccgaatagcgcccttccccttgcccggcgtt atgatttgcccaaacaggtcgctgaaatgcggctggtg cgcttcatccgggcgaaagaaccccgtattggcaaatattgacggccagttaagccattcatgccagtaggcgcgcggacgaaa gtaaacccactggtgataccattcgcgagcctccggatgacgaccgtagtgatgaatctctcctggcgggaacagcaaaatatc acccggtcggcaaacaaattctcgtccctgatttttcaccaccccctgaccgcgaatggtgagattgagaatataacctttcat tcccagcggtcggtcgataaaaaaatcgagataaccgttggcctcaatcggcgttaaacccgccaccagatgggcattaaacga gtatcccggcagcaggggatcattttgcgcttcagccatacttttcatactcccgccattcagagaagaaaccaattgtccat ttgcatcagacattgccgtcactgcgtcttttactggctcttctcgctaaccaaaccggtaaccccgcttattaaaagcattct gtaacaaagcgggaccaaagccatgacaaaaacgcgtaacaaaagtgtctataatcacggcagaaaagtccacattgattattt gcacggcgtcacactttgctatgccatagcatttttatccataagattagcggatcctacctgacgctttttatcgcaactctc tactgtttctccatacccgttttttgggctaacaggaggaattaaccatgaaacagcaggaagaagaggcggaacgcttgcgcc gtattcaagaggagatggaaaaggaacgcaaacgccgtgaagaggatgagaagcgccgtcgtaaggaggaggaagagcgtcgc tgaagttggaaatggaagcgaaacgtaagcaagaggaagaagagcgcaaaaagcgtgaggatgacgaaaaacgtatccaagcgg agaccgggtcaggaacagagaactt t tttccaaaacttt aaatccgtcacaacgtggaagatggtagcgtgcagctggcgg atcattatcagcagaataccccgattggtgatggcccggtgctgctgccggataatcattatctgagcacccagagcgttctga gcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgttaccgccgcgggcattacccaccatcatcatcacc atggaagcggcatgagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggcc at aatttagcgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggtaaac tgccggttccgtggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgcc atgatttctttaaaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacct t aaaccc gtgcggaagttaaatttgaaggcgataccctggtgaaccgcattgaactgaaaggtattgattttaaagaagatggcaacattc tgggtcataaactggaatataatttcaacagccataatgtgtatattaccgccgataaacagaaaaatggcatcaaagcgtaac cgaagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaac agaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggt gtgtggggtctccccatgcgagagt gggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctcctgagtaggacaaatccgccgggagcggatttgaacgttgcgaagcaacggccc ggagggtggcgggcaggacgcccgccataaactgccaggcatcaaattaagcagaaggccatcct acggatggcctttttgcg tttctacaaactcttttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttca ataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgt ttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatct caacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgct tgtggcgc ggtattatcccgtgttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagt ctcacc agtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggc caacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttga tcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcg caaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggacc acttctgcgctcggcccttccggctggctggtttattgctgat aatctggagccggtgagcgtgggtctcgcggtatcattgc agcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatag acagatcgctgagat ggtgcctcactgattaagcattggt actgtcagaccaagtttactcatat tactttagattgattt aaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttc gttccactgagcgtcagaccccttaataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttgctctgaaaacga aaaaaccgccttgcagggcggtttttcgaaggttctctgagctaccaactctttgaaccgaggtaactggcttggaggagcgca gtcaccaaaacttgtcctttcagtttagccttaaccggcgcatgacttcaagactaactcctctaaatcaattaccagtggctg ctgccagtggtgcttttgcatgtctttccgggttggactcaagacgatagttaccggataaggcgcagcggtcggactgaacgg ggggttcgtgcatacagtccagcttggagcgaactgcctacccgga ctgagtgtcaggcgtggaatgag caaacgcggccat890564-0003-W001

[0451] aacagcggaatgacaccggtaaaccgaaaggcaggaacaggagagcgcacgagggagccgccagggggaaacgcctggtatctt tatagtcctgtcgggtttcgccaccactgatttgagcgtcagatttcgtgatgcttgtcaggggggcggagcctatggaaaaac ggctttgccgcggccctctcacttccctgttaagtatcttcctggcatcttccaggaaatctccgccccgttcgtaagccattt ccgctcgccgcagtcgaacgaccgagcgtagcgagtcagtgagcgaggaagcggaatatatcctgtatcacatattctgctgac gcaccggtgcagccttttttctcctgccacatgaagcacttcactgacaccctcatcagtgccaacatagtaagccagt taca ctccgctagcgctgaggtcagcttgcccacgtagaccgacccgtcaagccgtcaattgtctgattcgttaccaa

[0452] SEQ ID NO: 10 - TEV-N164-A163 Biosensor Polypeptide _ MKQQEEEAERLRRIQEEMEKERKRREEDEKRRRKEEEERRMKLEMEAKRKQEEEERKKREDDEKRIQAETGSGTENLYFQNFKI RHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHHHHHHGSGMSKGEELFTGW PILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKS7XMPEGYVQER TISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIK _

[0453] SEQ ID NO: 11 - Circularly Permutated sfGFP Nucleotide Sequence _ atgcagaaaaatggcatcaaagcgaactttaaaatccgtcacaacgtggaagatggtagcgtgcagctggcggatcattatcag cagaataccccgattggtgatggcccggtgctgctgccggataatcattatctgagcacccagagcgttctgagcaaagatccg aatgaaaaacgtgatcatatggtgctgctggaatttgttaccgccgcgggcattacccaccatcatcatc ccatggaagcggc atgagcaaaggtgaagaactgtttaccggcgttgtgccgattctggtggaactggatggtgatgtgaatggccataaatttagc gttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccctgaaatttatttgcaccaccggtaaactgccggttccg tggccgaccctggtgaccaccctgacctatggcgttcagtgctttagccgctatccggatcatatgaaacgccatgatttcttt aaaagcgcgatgccggaaggctatgtgcaggaacgtaccattagcttcaaagatgatggcacctataaaacccgtgcggaagtt aaatttgaaggcgat ccctggtgaaccgcattgaactgaaaggtattgattttaaagaagatggcaacattctgggtcataaa ctggaatataatttcaacagccataatgtgtatattaccgccgataaa

[0454] SEQ ID NO: 12 - Circularly Permutated sfGFP Polypeptide Sequence (FIG. 1B) _ MQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHHHHHHGSG MSKGEELFTGWPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFF KSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADK _

[0455] SEQ ID NO: 13 - Protease Biosensor DNA Sequence _ atgaaacagcaggaagaagaggcggaacgcttgcgccgtattcaagaggagatggaaaaggaacgcaaacgccgtgaagaggat gagaagcgccgtcgtaaggaggaggaagagcgtcgcatgaagttggaaatggaagcgaaacgtaagcaagaggaagaagagcgc aaaaagcgtgaggatgacgaaaaacgtatccaagcggagaccgggtcaggaacagagaacttatatttccaaaactttaaaatc cgtcacaacgtggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctg ccggataatcattatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaattt gttaccgccgcgggcattacccaccatcatcatcaccatggaagcggcatgagcaaaggtgaagaactgtttaccggcgttgtg ccgattctggtggaactggatggtgatgtgaatggccataaatttagcgttcgtggcgaaggcgaaggtgatgcgaccaacggt aaactgaccctgaaatttatttgcaccaccggtaaactgccggttccgtggccgaccctggtgaccaccctgacctatggcgtt cagtgcttt gccgctatccggatcatatgaaacgccatgatttctttaaaagcgcgatgccggaaggctatgtgcaggaacgt accattagcttcaaagatgatggcacctataaaacccgtgcggaagttaaatttgaaggcgataccctggtgaaccgcattgaa ctgaaaggtattgattttaaagaagatggcaacattctgggtcataaactggaatataatttcaacagccataatgtgtatatt accgccgataaacagaaaaatggcatcaaagcg

[0456] SEQ ID NO: 14 - Protease Biosensor Polypeptide Sequence (FIG. 1C) _ MKQQEEE \ERLRRIQEEMEKERKRREEDEKRRRKEEEERRMKLEMEAKRKQEEEERKKREDDEKRIQ \ETGSGTENLYFQNFKI RHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHHHHHHGSGMSKGEELFTGW PILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQER TISFKDDGTYK RAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKA _

[0457] SEQ ID NO: 15 - Circularly Permutated sfGFP-MBP Enteropeptidase C-term DNA Sequence _ ttatgacaacttgacggctacatcattcactttttcttcacaaccggcacggaactcgctcgggctggccccggtgcatttttt aaatacccgcgagaaatagagttgatcgtcaaaaccaacattgcgaccgacggtggcgataggcatccgggtggtgctcaaaag cagcttcgcctggctgatacgttggtcctcgcgccagcttaagacgctaatccctaactgctggcggaaaagatgtgacagacg cgacggcgacaagcaaacatgctgtgcgacgctggcgatatcaaaattgctgtctgccaggtgatcgctgatgtactgacaagc ctcgcgtacccgattatccatcggtggatggagcgactcgttaatcgcttccatgcgccgcagtaacaattgctcaagcagatt tatcgccagcagctccgaatagcgcccttccccttgcccggcgttaatgatttgcccaaacaggtcgctgaaatgcggctggtg cgcttcatccgggcgaaagaaccccgtattggcaaatattgacggccagttaagccattcatgccagtaggcgcgcggacgaaa gtaaacccactggtgataccattcgcgagcctccggatgacgaccgtagtgatgaatctctcctggcgggaacagcaaaatatc acccggtcggcaaacaaattctcgtccctgatttttcaccaccccctgaccgcgaatggtgagattgagaatataacctttcat tcccagcggtcggtcgataaaaaaatcgagataaccgttggcctcaatcggcgttaaacccgccaccagatgggcattaaacga gtatcccggcagcaggggatcattttgcgcttcagccatacttttcatactcccgccattcagagaagaaaccaattgtccata ttgcatcagacattgccgtcactgcgtcttttactggctcttctcgctaaccaaaccggtaaccccgcttattaaaagcattct gtaacaaagcgggaccaaagccatgacaaaaacgcgtaacaaaagtgtctataatcacggcagaaaagtccacattgattattt gcacggcgtcacactttgctatgccatagcatttttatccataagattagcggatcctacctgacgctttttatcgcaactctc tactgtttctccatacccgttttttgggctaacaggaggaattaaccatgagcagcggcggtggctttaaaatccgtcacaacg tggaagatggtagcgtgcagctggcggatcattatcagcagaataccccgattggtgatggcccggtgctgctgccggataatc attatctgagcacccagagcgttctgagcaaagatccgaatgaaaaacgtgatcatatggtgctgctggaatttgttaccgccg cgggcattacccaccatcatcatcaccatggaagcggcatgagcaaaggtgaagaactgtttaccggcgttgtgccgattctgg890564-0003-W001

[0458] tggaactggatggtgatgtgaatggccataaatttagcgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaactgaccc tgaaatttatttgcaccaccggtaaactgccggttccgtggccgaccctggtgaccaccctgacctatggcgttcagtgcttta gccgctatccggatcatatgaaacgccatgatttctttaaaagcgcgatgccggaaggctatgtgcaggaacgtaccattagct tcaaagatgatggcacctataaaacccgtgcggaagttaaatttgaaggcgataccctggtgaaccgcattgaactgaaaggt ttgattttaaagaagatggcaacattctgggtcataaactggaatataatttcaacagccataatgtgtatattaccgccgaaa aacagaaaaatggcatcaaagcggatgccggcagcagctcgaacaacaacaacaata caataacaacaacagctctggcggta tgggaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggtctcgctgaagtcggtaagaaattcg agaaagataccggaattaaagtcaccgtt gagcat ccggataaactggaagagaaattcccacaggttgcggcaactggcgatg gccctgacat atct ctgggcacacgaccgctttggtggctacgctcaatctggcctgttggc gaaatcaccccggacaaag cg tccaggacaagctg atccgtttacctgggatgccgtacgt acaacggcaagc gattgc acccgatcgctg tgaag cgttatcgc ga tt taacaaagatctgc gccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactga aagcgaaagg a gagcgcgctgatgttcaacctgcaagaaccg acttcacctggccgctgat gc gc gacgggggt atg cgttcaagtatgaaaacggcaagtacgaca taaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctgg ttgacctgat aaaaacaaacacatgaatgcagacaccgattac ccatcgcagaagctgcctt aataaaggcgaaacagcga tgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaagtgaattatggtgtaacggtactgccgacct caagg gtcaaccatccaaaccgttcgttggcgtgc gagcgcaggt ttaacgccgccagtccgaacaaagagctggcaaaagag tcc tcgaaaact tc gctgactgatgaagg c ggaagcggtt ataaagacaaaccgctgggtgccgtagcgctgaagtct acg aggaagagt ggcgaaagatccacgtat gccgccaccatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcaga tgtccgctt ctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaagccctgaaagacg cgcagacttaaccgaagcttggctgttttggcggatgagagaagattttcagcctgatacagat aaatcagaacgcagaagcg gtctgataaaacagaat tgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgt gcgccgatgg agtgtgggg ctcccca gcgagag agggaac gccaggcatcaaat aaacgaaaggctcagtcgaaagac tgggcct tcgt tt tctg tgtttgtcggtgaacgctctcctgagtaggacaaa ccgccgggagcggatttgaacgt gcg aagcaacggcccggagggtggcgggcaggacgcccgccataaac gccaggcatcaaattaagcagaaggccatcctgacggat ggccttt tgcg ttctacaaactcttttg ttatttttctaaatacattcaaa a gtatccgctcatgagacaataaccctg ataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcatt ttgccttcctgtttt gctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagt gggtgcacgagtggg tacat cgaactggatctcaacagcggtaagatcct gagag tttcgccccgaagaacg tt ccaa gatgagcacttt aaag tct gctatgtggcgcggt t atcccgtgttgacgccgggcaagagcaactcggtcgccgcatacac at ctcagaatgact ggt tgagtactcaccagtcacagaaaagcatct acgga ggcatgacagtaagagaat tgcagtgctgccataaccatgagtga taacactgcggccaact ac tctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgt aactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggc aacaacg tgcgcaaactat aactggcgaactact actctagcttcccggcaacaattaa agactggatggaggcggata ag tgcaggaccact ctgcgctcggccct ccggc ggctggt tattgctga aaatctggagccggtgagcgtgggtctcg cggtatcat gcagcactggggccagatgg aagccctcccgt tcgtagt atctacacgacggggagtcaggcaact gga tgaacgaaatagacagatcgctgagatagg gcctcactgattaagcat ggtaac gtcagaccaagtt actcat a a act ttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatccctta acgtgagttttcgttccactgagcgtcagaccccttaataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttg ctctgaaaacgaaaaaaccgccttgcagggcggtttttcgaaggttctctgagctaccaactctttgaaccgaggtaactggct tggaggagcgcagtcaccaaaacttgtcctttcagtttagccttaaccggcgcatgacttcaagact actcctctaaatcaat taccagtggctgctgccagtggtgcttttgcatgtctttccgggttgg ctcaagacgatagttaccggataaggcgcagcggt cggactgaacggggggttcgtgc t cagtccagcttggagcgaactgcctacccggaactgagtgtcaggcgtggaatgagac aaacgcggccataacagcggaatgacaccggtaaaccgaaaggcaggaacaggagagcgcacgagggagccgccagggggaaac gcctggtatctttatagtcctgtcgggtttcgccaccactgatttgagcgtcagatttcgtgatgcttgtcaggggggcggagc ctatggaaaaacggctttgccgcggccctctcacttccctgttaagtatcttcctggcatcttccaggaaatctccgccccgtt cgtaagccatttccgctcgccgcagtcgaacgaccgagcgt gcgagtcagtgagcgaggaagcggaatatatcctgtatcaca tattctgctgacgcaccggtgcagccttttttctcctgccacatgaagcacttcactgacaccctcatcagtgccaacatagt agccagt tacactccgctagcgctgaggtcagcttgcccacgtagaccgacccgtcaagccgtcaattgtctgattcgttacc aa

[0459] SEQ ID NO: 16 - Circularly Permutated sfGFP-MBP Enteropeptidase C-term Polypeptide Sequence MSSGGGFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHHHHHHGSGMSK GEELFTGWPILVELDGDVNGHKFSVRGEGEGDAT GKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSA MPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITAEKQKNGIKADAGSSSNN NNNNNNNNSSGGMGIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYA QSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPY FTWPL IAADGGYAFKYENGKYDI KDVGVDNAGAKAGLTFLVDLI KNKHMNADTDYS I EAAFNKGETAMT I NGPWAWSNI DTS K VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMEN AQKGE IMPNI P QMSAFWYAVRTAVI NAAS GRQTVDEALKDAQT _

[0460] SEQ ID NO: 17 - Tobacco Etch Virus Protease Cleavage Site (generic) _

[0461] ENLYFQ / X _

[0462] SEQ ID NO: 18 - Tobacco Etch Virus Protease Cleavage Site of SEQ ID NO: 8, 10, and 14 _

[0463] ENLYFQ / N

Claims

890564-0003-W001CLAIMSWhat is claimed:

1. An engineered protein, comprising:a first portion of a parent protein;a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein; and a protease recognition sequence;wherein, in the engineered protein, the second portion of the parent protein is located N- terminal to the first portion of the parent protein, andwherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein.

2. The engineered protein of claim 1, wherein the second portion of the parent protein is operably linked to the N-terminus of the first portion of the parent protein.

3. The engineered protein of claim 1, wherein the protease recognition sequence is operably linked to the N-terminus of the second portion of the parent protein.

4. The engineered protein of claim 1, wherein the protease recognition sequence is directly fused to the N-terminus of the second portion of the parent protein.

5. The engineered protein of claim 1, wherein the protease recognition sequence is operably linked to the C-terminus of the first portion of the parent protein.

6. The engineered protein of claim 1, wherein the protease recognition sequence is directly fused to the C-terminus of the first portion of the parent protein.

7. The engineered protein of claim 1, wherein the protease recognition sequence destabilizes at least one intramolecular interaction of the engineered protein, such that proteolytic cleavage of the protease recognition sequence at least partially stabilizes the destabilized intramolecular interaction.890564-0003-W0018. The engineered protein of claim 7, wherein the intramolecular interaction is a hydrophobic interaction between at least two amino acid residues that form part of a hydrophobic cluster in the parent protein.

9. The engineered protein of claim 8, the wherein parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1152.

10. The engineered protein of claim 8, the wherein parent protein is derived from Aequorea victoria green fluorescent protein, and the intramolecular interaction involves amino acid residue 1161.

11. The engineered protein of claim 1, wherein the protease recognition sequence reduces activity of the engineered protein relative to the parent protein.

12. The engineered protein of claim 1, wherein proteolytic cleavage of the protease recognition sequence increases biological activity of the engineered protein.

13. The engineered protein of claim 1, wherein proteolytic cleavage of the protease recognition sequence restores the engineered protein to an active conformation.

14. The engineered protein of claim 1, wherein the parent protein is selected from an enzyme, a fluorescent protein, a transcription factor, or a receptor.

15. The engineered protein of claim 14, wherein the parent protein is a fluorescent protein.

16. The engineered protein of claim 15, wherein the fluorescent protein is a superfolder variant of green fluorescent protein.

17. The engineered protein of claim 16, wherein the superfolder variant of green fluorescent protein comprises one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, andA206V.890564-0003-W00118. The engineered protein of claim 1, wherein the protease recognition sequence is cleavable by a protease selected from TEV protease, Thrombin, caspase, Factor Xa, SUMO Protease, Trypsin, Enterokinase, or Endoproteinase AspN.

19. The engineered protein of claim 18, wherein the protease recognition sequence is configured to be recognized by Tobacco Etch Virus protease.

20. The engineered protein of claim 1, wherein the protease recognition sequence comprises ENLYFQ / X (SEQ ID NO: 17), where X represents an amino acid residue following a cleavage site.

21. The engineered protein of claim 1, wherein at least a portion of a beta sheet near a C- terminus of the first portion of the parent protein is sequentially last to fold.

22. The engineered protein of claim 1, wherein the protein comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 8, 10, 12, 14, or 16.

23. The engineered protein of claim 1, wherein the protein comprises an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 16.

24. The engineered protein of claim 1, wherein the protein is expressed by a nucleotide sequence having at least 90-99% identity to SEQ ID NO: 7, 9, 11, 13, or 15.

25. The engineered protein of claim 1, wherein the protein is expressed by a nucleotide sequence comprising SEQ ID NO: 7, 9, 11, 13, or 15.

26. A method for regulating activity of a protein, comprising:providing a protein comprising:a first portion of a parent protein;a second portion of the parent protein, wherein the second portion of the parent protein is C-terminal to the first portion of the parent protein in the parent protein;wherein, in the engineered protein, the second portion of the parent protein is located N-terminal to the first portion of the parent protein, and890564-0003-W001wherein the protease recognition sequence is located either N-terminal to the second portion of the parent protein or C-terminal to the first portion of the parent protein;a protease recognition sequence wherein the sequence of amino acid residues disrupts an interaction between at least two amino acid residues of the protein; andcontacting the protein with the protease to cleave the protease recognition sequence, thereby restoring the interaction between the at least two amino acid residues.

27. The method of claim 26, wherein the first portion of the parent protein is C-terminal to the second portion of the parent protein in the protein.

28. The method of claim 26, wherein the first portion of the parent protein is N-terminal to the second portion of the parent protein in the protein.

29. The method of claim 26, wherein the parent protein is a fluorescent protein, and wherein restoring the interaction increases fluorescence of the protein.

30. The method of claim 26, wherein the fluorescent protein is a superfolder variant of green fluorescent protein comprising one or more mutations selected from S30R, Y39N, N105T, Y145F, 1171V, andA206V.

31. The method of claim 26, wherein the protease is Tobacco Etch Virus protease.

32. A fusion protein, comprising:a translocated protein domain;a membrane association domain;a post-translational modification site; anda biosensor.

33. The fusion protein of claim 32, wherein the translocated protein domain comprises a signal peptide.890564-0003-W00134. The fusion protein of claim 33, wherein the signal peptide is positioned at an N-terminus of the fusion protein.

35. The fusion protein of claim 32, wherein the membrane association domain comprises a transmembrane domain.

36. The fusion protein of claim 35, wherein the transmembrane domain is a single-pass transmembrane domain.

37. The fusion protein of claim 32, wherein the post-translational modification site comprises a protease cleavage site.

38. The fusion protein of claim 37, wherein the protease cleavage site comprises a Tobacco Etch Virus protease cleavage site.

39. The fusion protein of claim 32, wherein the post-translational modification site comprises a phosphorylation site, a glycosylation site, or a SUMOylation site.

40. The fusion protein of claim 32, wherein the biosensor comprises a split fluorescent protein, a Förster resonance energy transfer fluorescent protein, a transcription factor, or an antibiotic metabolizing protein.

41. The fusion protein of claim 32, wherein the biosensor comprises a fluorescent protein.

42. The fusion protein of claim 32, wherein the translocated protein domain comprises a carbohydrase, an alpha-amylase, a protease, a subtilisin, insulin, beta-lactoglobulin, ovalbumin, albumin, an antibody, or a single-chain antibody fragment.

43. The fusion protein of claim 32, wherein the fusion protein comprises an amino acid sequence having at least 95-99% identity to SEQ ID NO: 8 or comprises an amino acid sequence of SEQ ID NO: 8.890564-0003-W00144. The fusion protein of claim 32, wherein the fusion protein is expressed by a nucleotide sequence having at least 95-99% identity to SEQ ID NO: 7 or a nucleotide sequence comprising SEQ ID NO: 7.

45. A system for regulating activity of a protein comprising:a fusion protein comprising:a translocated protein domain;a membrane association domain;a post-translational modification site; anda biosensor; anda membrane-localized protein comprising an enzymatic domain configured to modulate the post-translational modification site of the fusion protein.

46. The system of claim 45, wherein the membrane-localized protein is localized to a plasma membrane through S-palmitoylation or myristoylation.

47. The system of claim 45, wherein the enzymatic domain comprises a Tobacco Etch Virus protease.

48. The system of claim 45, wherein the enzymatic domain comprises a kinase, a SUMO- protein, or a glycosylation enzyme.

49. The system of claim 45, wherein modulation of the post-translational modification site comprises cleavage of the fusion protein, phosphorylation of the fusion protein, SUMOylation of the fusion protein, or glycosylation of the fusion protein.

50. The system of claim 45, wherein the biosensor comprises an amino acid sequence having at least 90-99% identity to SEQ ID NO: 10.

51. A method for regulating activity of a protein, comprising:expressing in a cell a fusion protein comprising a translocated protein domain, a membrane association domain, a post-translational modification site, and an biosensor;expressing in the cell a membrane-localized protein comprising an enzymatic domain;890564-0003-W001allowing the enzymatic domain to modulate the post-translational modification site of the fusion protein; anddetecting a change in a characteristic conferred by the biosensor.

52. The method of claim 51, wherein the post-translational modification site comprises a protease cleavage site, and wherein modulating the post-translational modification site comprises cleaving the fusion protein at the protease cleavage site.

53. The method of claim 51, wherein the biosensor comprises a fluorescent protein, and wherein detecting the change comprises detecting a change in fluorescence.

54. The method of claim 51, wherein the cell is an Escherichia coli cell, a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, a Yarrowia lipolytica cell, a Chinese hamster ovary cell, a murine myeloma cell, ora human embryonic kidney cell.

55. A nucleic acid molecule encoding the biosensor of claim 1 or the fusion protein of claim 32.

56. A vector comprising the nucleic acid molecule of claim 55.

57. A cell comprising the system of claim 45, the nucleic acid molecule of claim 55, or the vector of claim 56.

58. Use of the protein of claim 1; the method of claim 26, the fusion protein of claim 32; or the system of claim 45 for regulating protein function.